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ABSTRACT 
Adenosine is important in the regulation of vascular tone and the Equilibrative Nucleoside 
Transporter 1 (ENT1) is a regulator of adenosine concentrations.  Thus, changes in ENT1 
expression and activity may alter vascular tone regulation. We therefore examined the 
cardiovascular phenotype of ENT1-null (ENT1-/-) as compared to wild type mice (ENT1+/+). 
Heart rates (HRs) and blood pressures (BPs) of ENT1-/- and ENT1+/+ littermate male mice were 
obtained while conscious and anaesthetized, and metabolic data were collected over a 24 hr 
period. Vascular reactivity was assessed in aortic ring segments obtained from 3 month old 
ENT1-/- and ENT1+/+ mice during both normoxic and hypoxic conditions. Gene expression was 
obtained using qPCR. KCl administration mediated significantly greater constriction (~32% 
increase independent of tension applied or age) in ENT1-/- rings compared to ENT1+/+. However, 
no significant differences between the two genotypes were observed for the different receptor 
agonists. KCl works independent of receptors and carries out direct vasoconstriction via 
depolarization whereas receptor agonists work indirectly through cellular signaling mechanisms. 
In hypoxic conditions, ENT1-/- mice exhibited diminished response to phenylephrine following 
pretreatment with increasing concentration of adenosine as well as in the presence of ENT1 
inhibitor NBMPR suggesting an ENT1 independent effect of NBMPR. Length tension curves on 
the aortas were carried out and resulted in  an increase in ENT1-/-curve when the same tension 
was applied. HR and BP analysis showed elevated blood pressure while the mice were 
conscious. Morphological assessment of vascularized tissues was performed using H&E and 
Alizarin Red Staining. Visualization of H&E stain yielded significant differences in luminal area 
however no significant differences were seen in arterial wall thickness between ENT1+/+ and 
ENT1-/- mice at the age of 3 months. Alizarin Red staining yielded no evidence of calcium 
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deposits in the arterial walls. The enhanced effect of KCl in ENT1-/- aortic rings suggests a 
physiological difference in the regulation of the vasoconstriction response. The increased blood 
pressure coupled with the stiffening of the aortic wall suggests an increase on the mechanical 
load of the heart, possibly the early stages of hypertension. The studies suggest a vascular 
phenotype associated with a loss of ENT1. This model will continue to aid in unraveling the role 
of adenosine in vascular regulation. 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: adenosine, equilibrative nucleoside transporter 1 
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1.1 Adenosine and Receptor Signaling 
Adenosine is a molecule that is found ubiquitously throughout the body. It functions in 
cellular signaling and ATP (adenosine triphosphate) formation, which contributes to energy 
supply within tissues [1]. Adenosine formation and catabolism take place both intra- and extra-
cellularly and require either adenosine monophosphate (AMP) or S-adenosylhomocysteine [2].  
The enzyme 5ʹ-nucleotidase is responsible for adenosine formation from substrate AMP 
[3]. A distinction is made between the extracellular and intracellular formation of adenosine by 
way of renaming the enzyme ecto-5ʹ-nucleotidase (CD73) when dealing extracellularly, and 
this is done because this particular enzyme does not participate in the formation of intracellular 
adenosine. Similar to CD73, the intracellular 5ʹ-nucleotidase has the ability to hydrolyze 
multiple 5ʹ-monophosphates but its affinity for AMP is much greater. AMP is derived from 
ADP (adenosine diphosphate) and ATP, and within the cytosol, a decrease in the need for energy 
and therefore decrease in ATP generation results in more adenosine production.  
The breakdown of nucleotides is performed by a cascade effect in which using the 
example of ATP or ADP, the ecto-apyrase CD39 converts to AMP, and CD73 further converts 
AMP to adenosine [4]. Extracellular purinergic modulation is achieved by CD39, functioning as 
a family of nucleotidases that hydrolyze the di- and triphosphate nucleotides, whereas the 
glycosyl phosphatidylinositol linked membrane bound glycoprotein CD73, functions to 
hydrolyze extracellular nucleoside monophosphates [5,3] (Figure 1.1). 
 
 
 Figure 1.1: Intracellular and extracellular adenosine formation pathways.
formation and catabolism takes place both intra
adenosine monophosphate (AMP) or 
responsible for adenosine formation from substrate AMP intracellularly. CD39 converts ATP 
and ADP to AMP, and CD73 further converts AMP to adenosine extracellularly.
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Hydrolysis occurs in the S -adenosylhomocysteine pathway by way of S-
adenosylhomocysteine hydrolase (SAH) [2]. Adenosine tightly binds to SAH which, studies 
have suggested, confers protection to adenosine from the actions of adenosine deaminase, in 
addition to forming a pool of cytosolic adenosine. 
Adenosine deaminase (ADA), adenosine kinase (AK) and membrane transport are 
responsible for the inactivation and removal of adenosine from tissues. All three pathways are 
widely distributed in mammalian tissues. ADA acts as an enzyme that degrades adenosine into 
inosine and ammonia, whereas AK catalyzes the formation of AMP from adenosine. ADA is 
markedly found in endothelial cells, vascular smooth muscle and the heart, and with its high 
affinity for adenosine, when cytosolic adenosine concentrations are high; ADA is a major 
pathway of adenosine degradation [1].  
 During resting conditions, AK is the predominant pathway. Its higher affinity for 
adenosine results in near maximum saturation of adenosine kinase, which indicates that during 
resting conditions, a high level of AMP production is occurring. The last form of removal of 
adenosine, membrane transport, is achieved through two mechanisms of nucleoside transport; the 
equilibrative bi-directional facilitators and the concentrative, inwardly directed Na+ /nucleoside 
co-transporters. Membrane transport into cells is required for both ADA and AK pathways and is 
a required association for adenosine metabolism [1]. 
The metabolism of AMP to adenosine is followed by activation of a multitude of G-
protein coupled receptors [3]. A further source for nucleotide stores is the diet, and the body also 
possesses many mechanisms for the absorption and subsequent incorporation into the tissues [6].  
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Inosine is a direct metabolite of adenosine, and in the microvasculature it further converts 
to hypoxanthine, xanthine, and subsequently uric acid and reactive oxygen species. During 
reperfusion both adenosine and inosine are released from the ischemic cells by way of ENT1, 
facilitating the conversion of adenosine and inosine and so forth. As substrates for xanthine 
oxidase, both metabolites hypoxanthine and xanthine catalyze the formation of superoxide 
radicals on reperfusion [1]. 
Nucleosides, nucleotides and nucleobases are all inherently linked. Their role within the 
body is important for many biological processes. Biological molecules such as nucleobases are 
components of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The nucleobases 
guanine, adenine, cytosine and thymine, collectively known as purines and pyrimidines, are the 
foundation of all nucleosides and nucleotides [7] (Figure 1.2). Nucleotide formation occurs when 
the nucleoside is mono-phosphorylated, di-phosphorylated or tri-phosphorylated.  
This conversion between nucleobases, nucleosides and nucleotides is constantly 
occurring throughout biological processes. These interconverting biological molecules are 
important in biological processes including serving as direct sources of metabolic energy, as well 
as structural and regulatory functions [8]. Nucleotide pools are utilized for DNA and RNA 
formation; the building blocks of NTP and dNTPs.  Further important biological processes 
include formation of nucleoside triphosphates (ATP, GTP, CTP and UTP) in which ATP and 
GTP play large roles in the supply of energy, and cell signaling by way of cyclic AMP and cyclic 
GMP [9] (Figure 1.3). It is unclear as to which sources contribute most to the nucleotide stores, 
however, it is believed that production and salvage mechanisms and by-products of cellular 
turnover, are sufficient to maintain cellular function. 
  
Figure 1.2: Structures of Purines and Pyrimidines
thymine and cytosine are collectively known as purines and 
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. The nucleobases adenine, guanine, 
pyrimidines. 
 
  
Figure 1.3: Structures of Adenosine, AMP, ADP and AT
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 Biological molecules such as nucleobases are components of deoxyribonucleic acid 
(DNA) and ribonucleic acid (RNA). The nucleobases are collectively known as purines, guanine 
and adenine, and pyrimidines, cytosine and thymidine, are the foundation of all nucleosides and 
nucleotides. Adenosine has been identified as a purine that is important in cell signaling via 
purine receptors. Purine receptors are broken down into two main families: (1) P1 receptors 
(adenosine receptors) which are important in cell signaling; and (2) P2 receptors. P2 receptors 
recognize nucleoside triphosphates, and are further divided into two unique receptor families:  
(1) G protein-coupled receptors (GPCR) and (2) ligand-gated ion channels [9]. 
The cellular signaling by adenosine is mediated by specific GPCR. Like other GPCRs, 
the adenosine receptors possess seven transmembrane domains of hydrophobic amino acids with 
the N-terminal lying extracellular and the C-terminal within the cytoplasm. Ligand binding 
occurs within the three dimensional arrangement of the α-helical transmembrane domain [10].   
Four subtypes have been identified within the adenosine receptor family. Subtypes are based on 
various molecular, biochemical and pharmacological factors:  (1) A1; (2) A2A; (3) A2B; and (4) A3 
[11]
.
 
The A1 receptor is most widely recognized of the four subtypes.  It functions through 
inhibitory G proteins to inhibit adenylate cyclase, causing a decrease in the second messenger 
cyclic adenosine monophosphate (cAMP), affecting cAMP-dependent protein kinases. This 
results in a decrease in phosphorylation of various proteins. The inhibition of adenylate cyclase 
by way of A1 receptors also restricts the activities of other agents that act via adenylate cyclase 
activity [1].  
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The A1 receptor has additional signaling properties which cause the activation of 
phospholipase C (PLC), resulting in downstream cascade effects of up-regulation of inositol 
1,4,5-trisphosphate (IP3), diacylglycerol (DAG) and increased mobilization of Ca2+  from the 
sarcoplasmic reticulum[1]. 
The distribution of A1 receptors varies between tissues. High levels of A1 receptors can be 
found throughout the central nervous system (CNS), and are important in reducing oxygen 
consumption during events of hypoxia or ischemia, resulting in a neuroprotective effect [1]. A1 
receptors are also found within the kidney and within heart tissues; affecting filtration rate, renin 
secretion and neurotransmitter release within the kidney, and mediating cardiac depression 
within the heart. The A1 receptors also affect blood vessel tone although the effects are rare in 
comparison to others in the P1 receptor family due to decreased receptor distribution [1]. 
A2A receptors activate adenylate cyclase with the coupling of the G protein Gs 
(stimulatory). When the A2A receptors are activated, cAMP increases, which affects many 
downstream signaling pathways, including the initiation of protein kinase A (PKA) pathway and 
inhibiting the mitogen-activated protein (MAP) kinase pathway [12]. The results of the 
activation of A2A receptors are in stark contrast to that of A1 receptors.  
The A2A receptors can be found in the vascular smooth muscle, the CNS, platelets, 
immune tissues and endothelium. These receptors, along with A2B, are the main adenosine 
receptors that are expressed within the vasculature and are associated with vasodilatory effects 
[13]. The distribution of A2A receptors seems to be variable between blood vessels, mediating 
vasodilation in some while not present in others; receptors in the pulmonary arteries appear to be 
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A2B whereas those in the smaller arteries appear to be A2A subtype. Oftentimes, when no effect 
can be seen through A2A receptor activation, relaxation is mediated through the A2B receptor [9]. 
A2B signaling pathway involves stimulation of adenylate cyclase and activation of PLC 
and IP3. This receptor possesses a lower affinity for adenosine than the A2A receptor. Although 
found ubiquitously throughout the body of most species, the abundance of this receptor is 
actually minor; and for receptor activation and subsequent response to occur, a large quantity of 
adenosine must be present [9]. 
A3 receptors, which are found in the plasma membrane of myocytes, have a similar effect 
as that of the A1 receptors, inhibition of adenylate cyclase, although receptor agonists typically 
have higher affinity at the A3 receptor than compared to the A1  [14,15].  Similar to A2B, the 
distribution is widespread however; controversy still shrouds its physiological role. Frequently 
the adenosine receptor family overlaps in tissue distribution resulting in multiple subtypes being 
expressed by the same cell. Expression such as this allows for adenosine to act on, and fine tune, 
multiple signaling pathways allowing independent receptor regulation [9] (Figure 1.4). 
The adenosine receptors have been identified in the heart and vasculature as well as other 
locations in the body, the A1 receptors having been described previously as having many of the 
cardioprotective functions of adenosine associated with it such as mediating the chronotropic, 
dromotropic and negative inotropic effects. A2A and A2B mediate the vasodilation that is 
produced by adenosine and may also have an impact on the cardioprotection along with A3 and 
A1 [16].  Studies done by Zhan et al. (2011) found that for a maximal A1 cardioprotective effect, 
i.e. beneficial A1 mediated post-ischemic function and decreased infarct size, more than one 
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receptor subtype must also be involved, thus supporting the theory that cardioprotection is 
mediated by interactions between receptor subtypes [17].  
 
 
 
 
 
 
 Figure 1.4: The Adenosine signaling pathway.
adenylate cyclase and cAMP up-
polarization, reduced intracellular calcium
results in the opposite effect. 
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1.2 Adenosine Transporters: ENTs and CNTs 
As nucleosides are hydrophilic molecules they require a specialized transport protein to 
cross cell membranes [8]. In mammalian cells there are two mechanisms of nucleoside transport, 
the equilibrative bi-directional facilitators (ENTs) and the concentrative, inwardly directed Na+ 
/nucleoside co-transporters (CNTs) which are found primarily in specialized epithelial tissues, 
including but not limited to the liver, kidney and small intestine [7].  
ENTs are found ubiquitously throughout the body as they are present in most, potentially 
all, cell types. They are required for the transport of the hydrophilic nucleosides across cell 
membranes [7]. The ENT family, also known in humans as SLC29, consists of four transport 
proteins in human cells, ENT1, ENT2, ENT3, and ENT4 (hENT1/2/3/4 to specify human origin).  
ENT1 and ENT2 are two of the major nucleoside uptake mechanisms of mammalian cells 
[8]. Located predominantly in the plasma membranes of cells, they are found throughout the 
body. ENT1 and ENT2 are distinguished functionally on the increased sensitivity of ENT1 to S6-
(4-nitrobenzyl) mercaptopurine riboside (NBMPR, nitrobenzylthioinosine) and by the ability of 
ENT2 to transport nucleobases [7]. Much less is known about ENT2 than ENT1 due in large part 
to ENT2 being present in conjunction with ENT1. These transporters are driven solely by the 
concentration gradient of nucleoside permeants [18].  Alternatively, ENT3 is thought to be a 
previously identified low affinity transport system for nucleosides in lysosomes, while not much 
is known about ENT4 subcellular distribution [8].  
In a study done by Barnes et al. (2006), levels of hENT4 mRNA were found in many 
adult and fetal tissues with particularly high levels of abundance in the adult heart, intestine, 
liver, pancreas, lymph nodes, kidney and the bone marrow [19]. ENT4 efficiently transports 
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adenosine but it is sensitive to extracellular pH levels [19]. Optimally, physiological pH of 7.4, 
ENT4-mediated adenosine transport activity is nearing zero. Within acidic pH levels of 5.5 its 
activity increases, suggesting that during ischemic conditions and subsequent acid build-up, 
ENT4 may play an important role in the regulation of extracellular adenosine concentrations 
[19]. 
Concentrative nucleoside transporters (CNT) are proteins encoded by three SLC28 genes 
(SLC28A1, SLC28A2, and SLC28A3), which represent CNT1, CNT2 and CNT3 respectively 
[20]. They function by promoting nucleoside transport into the cells against the concentration 
gradient by using the plasma membrane sodium ion gradient to generate energy while serving as 
transporters for adenine and other permeants, although selectivity for permeants are variable 
across CNT subtypes, and act as nucleoside drug import pumps [20]. CNT1 prefers pyrimidine 
nucleosides, CNT2 the purine nucleosides and CNT3 is involved in both substrates translocation.  
1.3 ENT Inhibitors 
The endogenous purine, adenosine is transported across cell membranes by the 
nucleoside transporters which are the major regulators of adenosine extracellular concentrations. 
Adenosine is the focus because it is the nucleoside that exhibits the highest affinity for facilitated 
diffusion by this system [21].  
The specificity of transport inhibitors has been measured using techniques in which the 
disappearance of adenosine from cell suspension and whole blood is quantified. Currently, there 
are reasonably selective adenosine uptake inhibitors for ENT1. 
NBMPR is a nucleoside analogue. It is the most specific ENT1 inhibitor that is currently 
known and as such, its introduction has led to an increased ability to characterize the nucleoside 
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transporter due to its high level of potency and specificity. It is selective for ENT1, and varies 
little between models with a Ki in erythrocytes of 10-9 – 10-7 and 10-9 in rat tissue, although rats 
only have ENT2 mediated uptake therefore often report higher values [22,23].  
There are many other well-known inhibitors of ENT, all with different specificities and 
limitations. Dipyridamole is an inhibitor of both ENT1 and ENT2 (equilibrative, insensitive) 
nucleoside transporters [24]. With a Ki value of 10-9 – 10-7 M it is an effective inhibitor however 
in addition to uptake inhibition it also is involved in phosphodiesterase inhibition which affects 
uptake [22].  Unlike NBMPR which has a similar affinity for ENT1 across species, dipyridamole 
sensitivity varies between rat, mouse and humans [25]. Oral treatments with dipyridamole have 
been shown to effectively increase concentrations of plasma adenosine and protect against 
ischemia-reperfusion injury in the forearm skeletal muscles of healthy individuals [26,27].   
Dilazep and draflazine are two additional inhibitors, both of which have been studied 
extensively. Draflazine has been a focus of study in cardiac tissue protection against damage 
resulting from ischemia. Draflazine is known to have an enhancing effect on extracellular 
adenosine concentrations and is relatively ineffective in the inhibition of secondary ENT (ENTs 
2-4) subtypes that a cell may possess [28]. Dilazep has similar potency to NBMPR as an 
inhibitor of ENT1 transport however it also has ENT2 inhibiting effects. However, dialzep is 2-3 
orders of magnitude more effective when inhibiting ENT1 than ENT2 depending on the model 
[22]. Dilazep is also able to inhibit adenosine uptake ex vivo but results in weak inhibition upon 
oral consumption [22]. Similar to dipyridamole, it is a useful tool in increasing plasma adenosine 
concentrations but its non-specific inhibition makes it difficult to measure the specific effects of 
the ENT1 [22]. 
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Currently there are only three known compounds that have a higher affinity for ENT2 
when compared to ENT1. They include 2-chloroadenosine, 2-fluoroadenosine and, soluflazine 
which is a draflazine analogue however, their affinity for ENT1 is too low to serve as a probe  
[28].  
1.4 Mouse Model 
A whole body ENT1-null mouse was developed by Doo-Sup Choi et al (2004) by the 
inactivation of the Slc29a1 gene on a C57BL/6J x 129X1/SvJ background [29,30]. Targeting 
vector pKSloxPNT-mod was used to target and eliminate 425 of 1,380 base pairs within the 
protein coding region of the Slc29a1 gene which encodes ENT1 [29,30]. Subsequently, exons 2 
and 4 were deleted [30]. The complete null allele was confirmed and heterozygous Slc29a1 mice 
which were phenotypically normal were mated to produce the ENT1-/- mouse as well as wild 
type littermate pairs (Figure 1.5). 
Upon initial study of these mice, there were no anomalies reported. The ENT1-/- mice 
showed a lower body weight when compared to littermate pairs. Otherwise there were no 
abnormalities in brain development, or spontaneous mortality rates [29]. 
The initial studies utilized these mice in an effort to identify the role of adenosine 
transport through ENT1 in the CNS in relation to alcohol consumption [29]. These studies found 
that ENT1-/- mice had lower response to ethanol however consumed greater amounts than their 
wild type littermates [29]. In addition, the ENT1-/- mouse exhibited reduced anxiety as measured 
through an elevated plus maze test [29]. The behavior witnessed was compared to decreased 
stimulation of A1 receptors by endogenous adenosine as opposed to a defect in the A1 receptor 
family [29]. 
17 
 
Work has been done within the Hammond laboratory using microvascular endothelial 
cells from the ENT1-/- mouse to assess the mechanisms of transport and metabolism of 
nucleosides and nucleobases [31]. Further work done within the Hammond laboratory has also 
lead to a novel finding in which ENT1 is seen to take a part in the regulation of calcification of 
soft tissue. Warraich et al. (2013) predicted that the ENT1-/- mouse model may be useful in 
investigating and evaluating therapeutics for the prevention of mineralization in diffuse 
idiopathic skeletal hyperostosis (DISH) [32].  DISH has been characterized by the ectopic 
calcification of spinal tissue and in mice lacking ENT1, development of calcified lesions similar 
to those found in DISH were observed. 
In addition, collaborators within the Coe laboratory at York University were able to 
establish a link between ENT1 and cardioprotection when they induced an ischemic event and 
measured infarct size. Significantly less myocardial infarction was found in the ENT1-/- when 
compared with the wild type littermates [33].  
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Figure 1.5: The generation of ENT1-null mouse. 
Permission to use copyrighted material: from Choi et al. 2004. The organization of the gene 
encoding mouse ENT1, the targeting construct, and the allele resulting from homologous 
recombination are shown. The targeted exons (2–4) are represented by boxes. The loxP 
sequences and the recognition sites for Cre recombination are presented by gray arrows. 
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1.5 Cardiovascular System 
The cardiovascular system is composed of the heart and the pulmonary and systemic 
circulatory systems. The heart is a structure composed of muscle which pumps blood throughout 
the body into the two circulatory systems. The lungs are supplied with blood via pulmonary 
circulation, and the systemic circulatory system transports the blood to and from the tissues and 
organs within the body. 
The heart pumps blood from venous to arterial, and is divided into left and right halves 
which are further divided into atria and ventricles. Deoxygenated blood is received through the 
right half of the heart, collected from peripheral tissues. It is then pumped into the pulmonary 
arteries, which then enters the pulmonary circulation. Oxygenated blood then leaves the 
pulmonary circulation to re-enter the heart through the pulmonary vein and subsequently be 
pumped out of the heart to disseminate to peripheral tissues via the aorta. The arteries which feed 
the peripheral tissue decrease in size as they extend further from the heart.  
1.5.1 Tunica Intima, Tunica Media and Tunica Adventitia 
Blood vessels throughout the body differ in size and complexity in terms of wall structure 
and as such are divided into six different groups: arteries, arterioles, capillaries, lymphatic 
vessels, veins and venules. All are composed of the same wall structure, the inner layer tunica 
intima, middle layer tunica media and the outer layer tunica adventitia, except for capillaries and 
post-capillary venules which have no tunica media [34]. 
The inner layer, tunica intima is comprised of an endothelial layer which is only a single 
cell layer thick. Tunica media is composed of circularly arranged smooth muscle cells. This layer 
is particularly well developed in arteries, where the ability to constrict and dilate is essential to 
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control blood pressure. Collagen and elastic fibrils comprise the tunica adventitia although in the 
veins it is mostly smooth muscle. This layer of the vessel wall is the most prominent in veins. In 
larger vessels, the walls require perfusion via small blood vessel and the vasa vasorum within the 
adventitia layer because both the adventitia and the media layers are too thick to be supplied with 
oxygen and nutrients by way of diffusion from the lumen [34](Figure 1.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1.6: Blood vessel wall organization. 
Surrounding the lumen is the tunica intima made up of a layer of endothelial cells. The tunica 
media, the bulk of the arterial wall is formed by smooth muscle cells, elastin and collagen. 
Finally the outer layer, the tunica adventitia, is made of collagen and elastin as well as 
fibroblasts.  
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Figure shows the three layer of an artery. 
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1.5.2 Aorta 
The aorta is the largest vessel in the body.  It transports oxygenated blood to every organ 
in the body from the left ventricle of the heart.  The anatomy of the aorta can be divided into 
seven sections; (1) the aortic valve, (2) the aortic root, (3) the ascending aorta, (4) aortic arch, (5) 
the descending thoracic aorta, (6) the abdominal aorta, and (7) the thoracoabdominal aorta. The 
vessel extends from the upper left side of the heart, forms an arch and descends [35].  
The descending thoracic aorta is the most posterior position of the aorta and supplies the 
spinal cord as well as the thymus and the lymph nodes with the mediastinal branches of the aorta. 
The aorta also has intercostal arteries that supply the intercostal spaces, and these can be seen 
when removing the connective tissue from the aorta upon dissection [34]. 
As mentioned previously, the aorta itself is also made up of different wall layers. The 
inner layer is the intima, the middle layer the media and the outer layer the adventitia, all of 
which have well defined roles in development, homeostasis and pathogenic degradation. The 
media is made up of elastic lamella that alternates with layers of muscle cells [36]. Composed of 
elastin, collagen and vascular smooth muscle cells this layer provides viscoelasticity. There are 
discrepancies in cellular origin within the aorta that result in differences in extracellular matrix 
microfibril density and vascular smooth muscle cell reactivity.  Consequently, analysis on the 
aorta must be done on isolated sections. 
1.5.3 Carotid Arteries 
The carotid arteries supply nutrients and oxygenated blood to the head and neck regions. 
The carotids are located on either side of the neck, the right common carotid branching from the 
brachiocephalic artery and the left common carotid branching directly from the aorta. The 
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internal carotid and external carotid arteries are both branches from the left and right common 
carotids. The internal carotid supplies the brain and eyes while the external supplies the throat, 
neck glands, tongue, mouth, scalp, face, and the meninges. 
1.6 Hypoxia 
Hypoxia is defined as a reduction in normal tissue oxygen tension levels. In other words, 
a decrease in the partial pressure of oxygen molecules dissolved within the blood plasma [37]. 
Hypoxic conditions have increased probability of occurring in vascular diseases, pulmonary 
diseases and cancers and lead to a variety of responses and production of growth factors. There is 
an initial shift from aerobic to anaerobic metabolism in which the method by which glucose is 
metabolized moves from the oxygen-dependent tri-carboxylic acid cycle to the oxygen-
independent metabolic pathway, also known as glycolysis. The process of glycolysis also has a 
secondary effect by which the pH is lowered by lactic acid generation. Haemoglobin production 
is increased in the renal cells and angiogenesis is induced by a large number of genes, including 
but not limited to angiopoietin-2, cyclooxygenase-2, hepatocyte growth factor, nitric oxide 
synthase, Tie-2 (an angiopoietin receptor), vascular endothelial growth factor (VEGF)-A, VEGF 
receptor-1 and placental growth factor (a member of the VEGF sub family).  
VEGF along with other factors including insulin-like growth factors and hepatocyte 
growth factors activate the protein tyrosine kinase receptor signaling pathway and subsequent 
myocardial hypertrophy [38]. These VEGF are crucial in embryogenesis and angiogenesis. There 
are three different VEGF receptors, VEGFR1, VEGFR2 and VEGFR3; VEGFR1 being a 
positive regulator of monocyte and macrophage migration, VEGFR2 involved in normal and 
pathological vascular endothelial cell, and VEGF3 playing a large role in lymphatic endothelial 
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cell development as well as function [39]. These VEGFR collectively induce cell migration, 
survival as well as proliferation [39]. 
Another hypoxia induced factor is nitric oxide (NO) which is the active moiety of the 
endothelium-derived relaxing factor (EDRF) [40]. As a key regulator of vascular homeostasis, 
under basal conditions, low levels of NO are produced by the endothelium to regulate vascular 
tone [41]. NO is released from endothelial cells into adjacent vascular smooth muscle cells 
(VSMC). The diffusion of NO into VSMC results in the activation of soluble guanylyl cyclase 
and the subsequent increase in the production of 3,5-cyclic guanosine monophosphate (cGMP). 
Following this, the primary mechanism of NO mediated vasorelaxation occurs [42]. The cGMP 
induced inhibition of voltage gated Ca2+ channels and the activation of protein kinases also 
results in vasorelaxation following the decreased cystolic Ca2+ concentrations and subsequent 
inhibition of calcium-calmodulin myosin light chain kinase complex formation. In addition to 
hypoxic conditions, the synthesis of NO by nitric oxide synthase (NOS) occurs in response to a 
wide variety of mechanical stimuli as well as biochemical stimuli such as adenosine. Stimulation 
of the cAMP pathway leads to subsequent stimulation of NO synthesis [43]. Inhibition studies on 
NO have yielded detrimental effects in the vasculature including pathological vasoconstriction, 
tissue ischemia and hypertension.  
Further effectors in the vasodilatory response include prostaglandins, and lipid 
compounds that are derived from fatty acids as well as others [44]. E-type prostaglandins are 
widely produced in the body and their receptors are part of the receptors classified as GPCRs. 
Prostaglandin E1 (PGE1) has vasodilatory properties and has been revealed to up-regulate VEGF 
as well as endothelial NOS. Prostaglandin E2 (PGE2) has also been shown to induce VEGF by 
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means of hypoxia-inducible factor 1α (HIF1α) which leads to the mechanistic downstream 
signaling discussed previously [45]. 
1.7 Vascular Protection and Preconditioning 
In the United States, acute myocardial infarction (AMI) is the leading cause of death with 
approximately 1 million occurring annually [46]. Adenosine has been known to play an 
important role in the regulation of coronary circulation, therefore impacting the ischemic period 
that occurs during an AMI. In the heart it has many functions including depression of the activity 
of the sinus and atrio-ventricular nodes, depression of atrial contractility and reduction of the 
contractile response to catecholamines [14]. ENTs affect the concentrations of adenosine 
available to adenosine receptors. Adenosine is dependent on nucleoside transporters to exit the 
cell. Adenosine interacts with receptors to accomplish a wide variety of effects including 
reduction in apoptosis, increased angiogenesis and vasodilation.  
The cellular signaling by adenosine is mediated by specific GPCRs. A2A, specifically, 
simulates adenylyl cyclase production by coupling to G proteins. This activation increases cAMP 
which affects many downstream signaling pathways including the activation of PKA pathway 
and inhibition of the MAP kinase pathway.  
Four types of receptors, A1, A2A, A2B, and A3, previously described and discussed, have 
been identified in the heart and vasculature as well as other locations in the body, the A1 
receptors having been previously described as having many of the cardioprotective functions of 
adenosine associated with it.  A2A and A2B mediate the vasodilation that is produced by 
adenosine and may also have an impact on the cardioprotection along with A3 and A1 [16]. The 
A1 receptors are participants in the protective effects of adenosine when dealing with ischemia 
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and reperfusion as the receptor mediates the chronotropic, dromotropic and negative inotropic 
effects [14]. Adenosine mediates these effects through the inhibition of neutrophil aggregation, 
adherence to, and injury of endothelial cells as well as platelet aggregation [14]. In addition, as a 
metabolite of ATP, adenosine is able to minimize ATP’s depletion during the ischemic event and 
increase ATP stores during reperfusion by means of glycolysis stimulation [14]. Finally, with 
adenosine’s vasodilation properties, the oxygen supply/demand ratio can be normalized [14]. 
Adenosine’s vasodilatory activity is mediated through the activation of GPCR which stimulate 
cAMP and subsequent cAMP dependent PKA downstream. PKA then phosphorylates numerous 
K+ channels, resulting in vasodilation. 
Cardioprotection is the reduction of myocardial infarction by rescuing cardiomyocytes at 
risk. There are various therapies aimed at reducing the incidence of myocardial infarction.  The 
differing therapies focus on the idea of the reduction of myocardial infarction by rescuing injured 
cardiomyocytes from death [38]. When an ischemic event occurs, a number of naturally 
occurring substances and proteins are up-regulated and released to act on injured cardiomyocytes 
activating cell survival signaling pathways [38]. Two cardioprotective responses have been 
established; the former occurring shortly after the ischemic event and the latter occurring within 
several days [47]. The second response involves an up-regulation of factors such as adenosine 
and VEGF, and the release from vascular tissues. Adenosine, specifically with A2B receptors, has 
been shown to stimulate VEGF production under normal as well as hypoxic induction [48]. 
The cardioprotective effects of adenosine have been shown in hearts exposed to short 
periods of ischemia. During these short ischemia periods, it has been observed that the release of 
adenosine protects the heart against injury sustained in future prolonged ischemic events and 
subsequently causes a decrease in infarct size [16]. The activation of adenosine receptors prior to 
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ischemia is known as one of the possible preconditioning pathways and confers cardioprotection 
by reducing infarct size, lethal arrhythmias and contractile dysfunction [47].  
1.8 Vascular Disorders 
Vascular dysfunction is a disorder in which there is poor function of the blood vessels; 
the function being disrupted and as a result, impaired blood flow arises. With the disruption in 
blood flow, the vasculature has difficulty getting oxygen and nutrients to the cells and waste 
removal does not proceed as efficiently. 
Myocardial damage, during and after the infarction, involves reactive oxygen species 
(ROS) [49]. Myocardial infarction is most often seen after an atherosclerotic plaque in a 
coronary artery has ruptured, eroded or ulcerated. This is followed by acute thrombosis of the 
vessel and the inhibition of blood flow [49]. The physiology behind the vasculature involves the 
perfusion, or blood flow, through tissues or organs. This circulation is determined primarily by 
the dynamics of the blood flow, the actual anatomy of the circulatory system and the different 
regulatory mechanisms that control heart and blood vessels. The blood flow is related to the 
pressure and resistance.  
A reduction in blood supply to tissues resulting in a shortage of oxygen and glucose 
required for cellular metabolism is known as ischemia. The primary method of intervention of an 
ischemic heart is reperfusion in hopes of myocardial salvage and patient survival. The depletion 
of ATP stores due to the ischemic effect elevates adenosine leading to the accumulation of 
inosine as well as other adenosine metabolites. Adenosine has been known to play an important 
role in the regulation of coronary circulation [14].  
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1.9 Rationale, Objectives and Hypotheses 
Given the prevalence of heart disease in the North American population it is expected 
that myocardial infarction will remain one of the leading causes of death for the foreseeable 
future. The World Health Organization (WHO) has estimated that cardiovascular disease will 
claim the lives of nearly 23.6 million people by the year 2030, as the population becomes 
increasingly elderly [49]. There is considerable evidence indicating a beneficial effect of 
adenosine following an AMI. Adenosine is important in the regulation of vascular tone, and 
ENT1 is a regulator therefore, with the change in ENT1 expression and activity there will be an 
impact on the mechanisms of vasodilation that are dependent on adenosine. The research done 
by Figueredo et al. (1999) was able to demonstrate the sustained cardioprotection against 
ischemia-reperfusion with chronic ethanol exposure, ethanol down-regulation of the transporter 
[50]. Ethanol has been observed to be an inhibitor of nucleoside transport, subsequently 
increasing adenosine in the extracellular spaces in in vitro studies [29]. There have been 
numerous accounts of increased vasodilation both within human and animal models [51]. 
Rose et al. (2009) completed research into cardioprotection within the heart and the 
conclusions suggest that the loss of ENT1 results in significantly smaller myocardial infarct size 
when compared with the littermate pairs [33]. Since then, Rose et al. (2011) have further 
addressed adenosine and inosine levels within the intracellular and extracellular spaces of 
cardiomyocytes and found extracellular adenosine increases as the cells are taken from normoxia 
to hypoxia, and similar results are found upon examination of the intracellular space when 
looking at inosine [52]. The effects seen in these previous studies suggest that a similar form of 
protection will exist in the vascular system. 
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In addition, studies done on cardioprotection in ecto-5’-nucleotidase (CD73) and 
ectonucleoside triphosphate diphosphohydrolase 1 (CD39) null mice have also found that these 
mice develop larger infarcts than their wild type counterpart [53]. A CD73 or CD39 null mouse 
is unable to break down ATP, ADP and AMP to adenosine therefore there would be a decrease 
in extracellular adenosine, and subsequent adenosine receptor activation. Further studies in these 
mouse models were done in which extracellular adenosine levels were increased via intra-arterial 
infusion resulting in increased cardioprotection by ischemia preconditioning [54]. Increases in 
phosphohydrolysis of ATP, ADP and AMP are a key factor in cardioprotection during a hypoxic 
challenge. Without CD73 and CD39, in other words, without large quantities of extracellular 
adenosine, the cardioprotective effects seen from adenosine were severely reduced. Hypoxia is 
believed to enhance cellular ATP production and release while also hydrolyzing adenine 
nucleotides, thereby increasing adenosine production [55].  Depending on the temporal 
relationship with onset of hypoxia and ATP release, it is also possible that the loss of ENT1 
initially results in an inadequate release of adenosine resulting in a delayed response to the 
hypoxic event. Loss of ENT1 may also result in higher levels of extracellular adenosine thereby 
causing a theoretical increase in cardiovascular protection.  
As mentioned previously, studies conducted by Choi et al. (2004) as well as Warraich et 
al. (2012) have also yielded evidence of morphological changes within the ENT1-null mice that 
has resulted from the loss of ENT1 [32]. Ectopic mineralization on spinal tissue has led to the 
examination of the parallels of this phenotype with the human disease known as DISH. An 8.7% 
decrease in body weight, as well as decreased fat as observed during the initial characterization 
of this mouse line also leads us to question what else may be changing within the vascular tissue, 
and the mouse model as a whole. 
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Hypothesis #1: Loss of ENT1 will lead to a vascular phenotype due to disruption of the normal 
purinergic homeostatic mechanism which is critical to vascular regulation. 
A working hypothesis was also formulated to examine a specific potential vascular 
characteristic. 
Hypothesis #2: Loss of ENT1 will result in an increase in interstitial adenosine levels leading to 
compensatory changes in the vasculature that would mimic preconditioning. 
To explore these hypotheses specific observations were outlined: 
1) Determine the baseline vascular characteristics of the ENT1 -/- mouse versus the ENT1+/+ 
mouse. 
2) Examine the aorta looking for structural differences between the ENT1 -/- and ENT1+/+ 
mouse. 
3) Examine the vascular tissue in response to hypoxic conditions. 
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Chapter 2: 
 Materials and Methods 
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2.1 Animal Protocol 
ENT1+/+, ENT1-/- and Charles River mice strain C57BL/6 were utilized in our studies. 
The ENT1-/- mice were generated through the targeted deletion for exons 2 to 4 of the gene 
encoding ENT1 by a cre-loxP targeting strategy [29]. The ENT1-/- were then bred with C57BL/6 
mice as previously described by Chen et al. (2007) [30]. Maintenance of the mouse colony 
occurred through the breeding of ENT1+/- (F1 generation) to obtain ENT1+/+ and ENT1-/- (F2 
generation) littermates. The care was in accordance with policies and guidelines outlined by the 
Canadian Council on Animal Care. The mice were used in accordance with the protocols 
approved by the Animal Use Subcommittee of the University of Western Ontario. Mice were 
housed under a 12 hour light/dark cycle and allowed unlimited access to rodent chow and 
drinking water. Male mice were utilized for this study to reduce the influences of hormonal 
cycles on the vascular functions that are being studied between mice. Mice were euthanized at 3-
4 months of age (12-19 weeks). 
2.2 Assessment of Vascular Reactivity in Aortas 
The vascular reactivity was assessed in aortic rings in accordance with previously 
published methods [38,56]. ENT1+/+ and ENT1-/- mice were anaesthetized with pentobarbital 
sodium (540 mg/kg ip), the chest wall was opened and the thoracic aorta was removed and 
transferred to a Petri dish containing Krebs physiological salt solution (KPSS) at 4˚C. The 
composition (mmol/L) of KPSS was NaCl 118.0, NaHCO3 25.0, d-glucose 11.1, KCl 4.72, 
CaCl22H2O 2.56, NaH2PO42H2O 1.13, MgCl26H2O 1.12, (-) ascorbic acid 0.114, and disodium 
EDTA 0.0297. Connective tissue and blood were removed carefully and four ring segments 
(2mm in length) from each aorta were cut and mounted in KPSS with an applied tension of 0.5 g, 
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to simulate physiological pressure, in organ baths individually gassed with 95% O2 and 5% CO2 
and maintained at 37˚C. The rings were equilibrated for 30 minutes before being maximally 
constricted with potassium chloride (KCl, final bath concentration, 100 mM) to assess viability. 
Additional pre-treatments of NBMPR (1 µM) or dimethyl sulfoxide (DMSO) (5 µL) were used 
as controls for KCl viability. Tissues were incubated in treatment 15 minutes prior to KCl.  
KPSS in the organ bath was changed three times after each treatment (Figure 2.1, i.).  
DMT (Danish Myo Tecnhnology) Myograph 620M was used to measure the tension 
generated. The unit consists of four single vessel myographs in a rack paired with a separate 
electronic unit. The data were rendered through a computer using PowerLab 4/30 
(ADInstruments) and LabChart 7 Pro software (ADInstruments, Australia) recorded the 
waveform. (Figure 2.1) 
2.2.1 Vasoconstrictor Dose-Response: 
Following a previously described tissue viability test, aortic rings were then exposed to 
increasing doses of phenylephrine (PE, 1 nM – 30 µM), prostaglandin F2α (PGF2α, 10 nM – 30 
µM) or serotonin (1 nM – 30 µM). The reason we are testing these receptor mediated 
vasoconstrictors rather than using KCl is because KCl works via cell depolarization. The 
addition of extracellular KCl results in a shift in resting membrane potential ultimately resulting 
in the release of calcium stores, KCl addition is not a natural occurrence and therefore cannot 
extrapolated to in vivo studies. The receptor mediated approach targets a specific subset of 
receptors and the mechanism of contraction results in signaling pathways that vary between 
receptor types. The contraction resulting from PE, PGF2α and serotonin administration was 
quantified by means of measuring directly the contraction generated. The receptor mediated 
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contraction responses were expressed as a percentage of the initial KCl maximum contraction. 
This preliminary test was done to establish a consistent vasoconstrictor to be used for subsequent 
dose-responses under various experimental conditions (Figure 2.1, ii.)  
2.2.2 Vasodilator Dose-Response: 
Vasodilation was tested to establish adenosine mediated vasoreactivity and to test 
whether the A2A receptor is responsible for vasodilation observed (Figure 2.1, iii.). Following the 
previously described tissue viability test, aortic rings were then incubated in the presence of 
PGF2α (concentration 80% of maximum, dose range 1 µM – 10 µM) alone or with PGF2α and 
SCH58261 (100 nM). SCH58261 is a selective antagonist for the A2A receptor. Following the 
incubation period an adenosine dose-response assay was carried out (100 nM – 1 mM). PGF2α 
was added 10 minutes before adenosine and increasing adenosine concentrations were added 
every two minutes thereafter. The relaxation resulting from adenosine administration was 
quantified by means of measuring directly the maximum PGF2α tension generated and the 
resultant vasodilation that occurred as a result of adenosine administration. The adenosine 
mediated relaxation responses were expressed as a percentage of the initial PGF2α maximum 
contraction.  
2.2.3 Phenylephrine Dose-Response following tissue exposure to Hypoxia:  
A dose-response assay was conducted following hypoxia to test whether a vascular 
protection effect was occurring (Figure 2.1, iv.). Following a previously described tissue viability 
test, aortic rings were then incubated in the presence of adenosine (30 µM – 300 µM) for 30 
minutes, NBMPR (1 µM) for 15 minutes, or NBMPR (1 uM) for 15 minutes followed by 
adenosine (300 µM) for 30 minutes. Aortic rings were then exposed to hypoxic conditions (95% 
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N2 – 5% CO2) for 60 minutes. NBMPR and/or adenosine were left in solution during hypoxia. 
Following hypoxic treatment KPSS was then changed three times and organ bath was switched 
back to normoxic (95% O2 – 5% CO2) conditions and tissue was incubated for an additional 30 
minute period. Aortic rings were then exposed to increasing doses of phenylephrine (PE, 1 nM – 
30 µM). The contraction resulting from PE administration was quantified by means of measuring 
directly the contraction generated. The PE-mediated contraction responses were expressed as a 
percentage of the initial KCl maximum contraction.  
2.3 Length Tension Curve: 
Tissue was equilibrated at room temperature (22˚C) in KPSS. Following the equilibrium 
period tissue was stretched an additive 50 microns every two minutes until tension generated 
reach a maximum and plateaued. As mentioned previously, the data were rendered through a 
computer using PowerLab 4/30 (ADInstruments) and LabChart 7 Pro software 
(ADInstruments,Australia) recorded the waveform.  
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Figure 2.1: Assessment of vasculature reactivity flowchart. All previous methods involving 
vascular reactivity as measured through DMT Myograph M620M are outlined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii. 
30min Incubation 
15min Incubation 
Wash 
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Mount Tissue on Organ Bath Prongs 
Incubate tissue for 30 minutes at 37˚C 
with 0.5g resting tension 
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Temperature without applying resting tension 
Test for viability: Add 100mM KCl and 
measure response after 10 minutes 
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i. 
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2.4 Histological: 
Aortas or carotid arteries were dissected under pressure, using gravity perfusion. Excised 
from three ENT1+/+ and three ENT1-/- mice of 3 – 4 months of age, the vessels were fixed in 10% 
neutral buffered formalin. Following standard histological processing, samples were embedded 
in paraffin and cut into 5 µm-thick serial sections. The aortic and carotid tissues were sectioned 
in the coronal plane, mounted on glass slides and baked at 45˚C for 48 hours. The Molecular 
Pathology Laboratory at Robarts Research Institute (London, Ontario) processed the samples 
prior to being embedded in paraffin. Sectioning was carried out by Diana Quinonez of the 
Hammond lab. Samples were then stained with hematoxylin and eosin (H&E) or Alizarin Red 
counterstained with H&E, which I carried out. Following staining protocol the sections described 
previously were dewaxed in xylene and rehydrated via consecutive immersion in decreasing 
concentrations of ethanol to aid in the visualization of the cell nuclei. Shur/Mount xylene-based 
liquid mounting media (Durham, NC) was used. 
 
2.5 Metabolic Cages: 
Oxygen consumption, carbon dioxide production, respiratory exchange ratio, food and 
water intake, sleep bouts, and physical activity were simultaneously measured in ten 3 – 4 month 
old mice by using the Comprehensive Lab Animal Monitoring System (CLAMS) interfaced 
using Oxymax software (Columbus Instruments, Columbus, OH). Mice were individually 
housed in the metabolic chambers and temperature was maintained at 24±1˚C. The mice were 
given free access to the standard rodent chow and water on a flow rate of 0.5 L/min. Metabolic 
chambers were maintained on a 12 hour light and 12 hour dark cycle with measurements being 
taken every 10 minutes for 48 hours following a habituation period of 16 hours. 
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Volume of oxygen consumption (VO2) and carbon dioxide production (VCO2) 
measurements were determined based on concentrations of gases supplied to the chambers as 
compared to concentrations of gases leaving the chambers and normalized to body mass 
(mL/kg/h). Respiratory exchange ratio (RER), a measure of metabolism substrate choice 
(carbohydrate vs. fat), was calculated from VCO2/VO2. An RER of 0.7 is indicative of high fat 
oxidation whereas high carbohydrate oxidation is shown by an RER of 1.0. Intense exercise or 
the synthesis of fat from carbohydrates is indicated by an RER that exceeds 1.0. Energy 
expenditure/heat (EE) (kcal/h) was calculated from RER and VO2 and corrected for body weight. 
The observed RER derives a caloric value (CV) which is then used with the VO2 to calculate 
heat. Heat = CV x VO2 where CV = 3.815 + 1.232 x RER. 
Total activity and ambulatory activity were obtained using the Opto-M3 Activity Monitor 
and Oxymax software algorithms (Columbus Instruments, Columbus, OH). Infrared photo beam 
breaks were monitored as counts on the X- and Y-axis and consecutive beam breaks were 
assessed as ambulatory movements.  
Food and water intake were obtained by using the Oxymax software algorithms 
(Columbus Instruments, Columbus, OH). Feed data is a measurement of how much food is 
consumed. Drinking is measured when the Volumetric Drinking Monitor detects the mouse 
licking a specifically designed sipper tube quantifying the volume of liquid made available to the 
test animal. 
Sleeping bouts were calculated based on sampling intervals taken every ten seconds. The 
mouse is considered sleeping if it fails to break the beams over the course of several sampling 
intervals. 
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2.6 Haemodynamics: 
Heart rate and blood pressure were determined using the CODA-6 non-invasive tail-cuff 
machine (Kent Scientific Corporation, Torrington, CT, USA,). Where needed, anaesthesia was 
induced using 1.5% isoflurane in O2. Anaesthetized animals were kept on a heated pad to prevent 
loss of body temperature. Animals were subjected to five acclimatization rounds (no data 
collection) followed by two separate acquisition cycles of 15 measurements each. There was a 60 
second rest between acquisition cycles. The tail cuff deflated over a period of 20 seconds during 
data acquisition. 
2.7 Quantitative Real Time PCR: 
At 3 – 4 months of age, littermate-paired wild type and ENT1-/- mice (N=3 for each 
genotype) were dissected to thoracic aortas inclusive of endothelial layer. Tissues were placed 
directly in 1 mL of PureZOL RNA isolation Reagent (Life Technologies, Wilmington, DE) and 
homogenized using a Dounce homogenizer. Total RNA was extracted using the Aurum Total 
RNA Fatty and Fibrous Tissue Kit (Mississauga, ON), using kit protocol and quantified using a 
NanoDrop 2000 spectrophotometer (Thermo Scientific, Mississauga, ON). For each sample, 210 
ng RNA was reverse transcribed into cDNA using Superscript II Reverse Transcriptase (Life 
Technologies). Gene expression patterns were determined by real-time PCR using the Bio-Rad 
CFX384 system. PCR reactions were run in triplicate, using 5 µM forward and reverse primers 
(primer sequences in Table 2.1) with 2X SsoFast EvaGreen Supermix (Bio-Rad, Mississauga, 
ON). The PCR program started with an initial 3 min at 95˚C for denaturing followed by 95˚C for 
10 s denaturing and 30 s annealing/elongation (temperatures provided in Table 2.1), for a total of 
40 cycles. Gene transcript levels were determined relative to Beta Actin. 
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The primers were designed using PrimerBank and Integrated DNA Technologies 
targeting the sequence specific to the gene of interest, always producing amplicons between 75 
and 175 base pairs in length. Optimization for primers was determined using 5-fold serial 
dilutions of cDNA that was synthesized from a mix of wild type heart, muscle, kidney, brain and 
intervertebral disc as well as aorta cDNA at a range of temperatures between 56-62˚C to 
optimize the annealing and elongation temperatures. Optimization was done in collaboration 
with Sumeeta Warraich of the Hammond laboratory. The specificity of the primers was 
determined by melt curve analysis.  
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Primer Sequence Table 2.1: 
 
Gene 
Name 
Primer Sequence (5’ to 3’) 
  
Annealing/Elongation 
Temperature (oC) 
Beta 
Actin 
Fwd – GGCTGTATTCCCCTCCATCG 
Rev – CCAGTTGGTAACAATGCCATGT 
60 
Catalase Fwd – TGGCACACTTTGACAGAGAGC 
Rev – CCTTTGCCTTGGAGTATCTGG 
60 
Ak Fwd – CTCAGTGGTTGATTCAGGAGC 
Rev – CAGCCTTACGCTTCAGGATCT 
60 
Ada Fwd – ACAATCAGAAGACCGTGGTGGCTA 
Rev – TCTTTACTGCGCCCTCATAGGCTT 
60 
ENT1 Fwd – CAAGTATTTCACAAACCGCCTGGAC 
Rev – GAAACGAGTTGAGGCAGGTGAAGAC 
56 
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2.8 Statistical Analysis: 
 
Data points are represented as means ± standard error of the mean (SEM). Curves were 
fitted using the software Graphpad Prism 5.03. Statistical analysis was performed using a two-
tailed student’s t-test or a Two-way ANOVA with Bonferroni post-tests to compare replicates 
where appropriate. The minimum level of significance was set at P<0.05 on a two-sided test. 
(Prism 5.03; GraphPad Software Inc., San Diego, CA). 
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Chapter 3: 
Results 
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3.1 Mouse full body analysis shows decreased weight and differences in metabolic activities.  
 Prior to reports of ectopic mineralization, the previous studies in the ENT1-null mouse 
model have yielded findings of no spontaneous mortality and showed a normal phenotype with 
no gross anatomical abnormalities. Body weight had been found to be approximately 8.7% lower 
in the ENT1-/- mouse and spontaneous mortality rates were similar between genotypes [29]. 
Warraich et al. (2012) had then found that ENT1 plays a role in bio-mineralization which they 
linked to diffuse idiopathic skeletal hyperostosis (DISH) [32]. 
In the present study, upon examination of the mouse litters at 3 – 4 months of age we also 
noticed the variance in body weight compared to the ENT1+/+ littermates. The ENT1-/- mouse 
was 25.3 ± 1.0 g and was significantly smaller than the 29.3 ± 0.8 g of ENT1+/+ mice (N=10; 
**P<0.01 Student’s t-test) (Figure 3.1, Panel J). To further analyze the cause of the weight 
difference, metabolic cages were used to examine food and water consumption along with 
respiratory exchange ratio, the amount of energy expended, the volume of oxygen consumed, 
carbon dioxide released, as well as the amount of movement seen over a 24 hour period during 
the light and dark cycles and the percentage of time spent sleeping (N=10; P<0.05 Student’s t-
test). During the dark cycle we observed significantly higher water consumption (Figure 3.1, 
Panel H), ambulatory movement (Figure 3.1, Panel D) and total movement (Figure 3.1, Panel E) 
in the ENT1-/- when compared to the ENT1+/+ (p<0.05). In addition, significant decrease was 
seen when analyzing the respiratory exchange ratio (Figure 3.1, Panel C) and the energy 
expenditure (Figure 3.1, Panel F). The RER value which is closer to 0.7 (0.9, P<0.05) in the 
ENT1-/-, when compared to ENT1+/+, is oxidizing more fat than carbohydrates. No significant 
differences were seen in volume of oxygen consumed (Figure 3.1, Panel A), volume of carbon 
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dioxide released (Figure 3.1, Panel B), food consumption (Figure 3.1, Panel G) or % of time 
spent sleeping (Figure 3.1, Panel I). 
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Figure 3.1. Metabolic analysis of ENT1+/+ and ENT1-/- mice using metabolic chambers as 
described previously in the methods. VO2 consumption (Panel A), VCO2 production (Panel B),  
Respiratory Exchange Rate analysis (Panel C), Ambulatory Activity per hr (Panel D), Total 
Activity per hour (Panel E), Energy Expenditure (Panel F), Food Consumption (Panel G), Water 
Consumption (Panel H), Body Weight (Panel J). N=10. % of time spent sleeping (Panel I). N=8. 
*Significant difference for 3 – 4 month old mice studies. (Student’s t test for unpaired 
experimental parameters,* P<0.05, **P<0.01) 
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3.2 Haemodynamics  
Further analysis of the baseline vascular characteristics led us to measure the heart rates 
of conscious and anaesthetized 3 – 4 month old ENT1+/+ and ENT1-/- mice (Figure 3.2, Panel A) 
were not significantly different although anaesthetized mice showed a trend towards increased 
heart rate (p=0.06, N=5). Anaesthetized ENT1+/+ mice hearts beat 517.0 ± 13.0 beats per minute 
(N=5) which was less than the ENT1-/- counterparts at 563.5 ± 16.9 beats per minute. The heart 
rate in awake ENT1+/+ mice was 676.5 ± 16.5 beats per minute (N=10) which is comparable to 
the ENT1-/- rate of 675.4 ± 12.5 beats per minute (N=11) (Figure 3.2, Panel A). In conscious 
mice (Figure 3.2, Panel B), the ENT1-/- mouse had significantly higher blood pressure compared 
to the ENT1+/+ counterparts. Systolic: 129.9 ± 5.4 mm/Hg, 149.5 ± 3.5 m/Hg; diastolic: 100.8 ± 
5.3 mm/Hg, 115.8 ± 2.6 mm/Hg; and mean arterial pressure (MAP): 110.1 ± 5.3 mm/Hg, 126.7 ± 
2.8 mm/Hg as observed from ENT1+/+ (N=10) and ENT1-/- (N=11) respectively. In anaesthetized 
mice (Figure 3.2, Panel C), the ENT1+/+ mouse blood pressure had no significant differences 
compared to ENT1-/- counterparts. Systolic: 101.5 ± 13.2 mm/Hg, 101.9 ± 8.6 mm/Hg; diastolic: 
72.9 ± 12.1 mm/Hg, 69.0 ± 9.5 mm/Hg; and mean arterial pressure: 82.1 ± 12.4 mm/Hg 79.7 ± 
9.2 mm/Hg as observed from ENT1+/+ (N=5) and ENT1-/- (N=5), respectively. These results 
were not expected as previous studies in the ENT1 mouse model found these mice to have an 
anxiolytic phenotype.  
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Figure 3.2. 3 – 4 month old mice were analyzed with a CODA-6 non-invasive tail-cuff 
machine as described previously in the methods. Heart rates of conscious and anaesthetized 
ENT1+/+ and ENT1-/- mice were determined (Panel A). Systolic, Diastolic and Mean Arterial 
Pressure were determined for conscious mice (Panel B) and isoflurane anaesthetized mice (Panel 
C). Conscious mice were N=10 for ENT1+/+ and N=10 for ENT1-/- and anaesthetized mice were 
N=5. *Significant difference for 3 – 4 month old mice blood pressure and heart rate studies. 
(Student’s t test for unpaired experimental parameters,* P<0.05, **P<0.01) 
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3.3 Visualization of isolated tissues with Haematoxylin and Eosin staining.  
Aortic and carotid tissues from 3 – 4 month old male ENT1+/+ and ENT1-/- mice, stained 
with H&E did not appear significantly different from each other (Figure 3.3). The tissues were 
analyzed based on layers of elastin and nuclei organization within the arterial walls. ENT1-/- 
aortic (Panel A) and carotid (Panel B) vessel walls were comparable to the ENT1+/+. Vasculature 
wall thickness (Figure 3.4, Panel A) and lumen circumference (Figure 3.4, Panel B) were also 
analyzed for morphological differences. The width of the aorta, measured in microns, was not 
significantly different in the ENT1-/- 28 ± 1 microns (N=6) when compared with the ENT1+/+ 
counterparts of 30 ± 2 microns (N=6, P<0.05). Similarly the carotid arteries were not 
significantly different in width with ENT1+/+ 18 ± 2 microns (N=4) and ENT1-/- 16 ± 2 microns 
(N=4, P<0.05). The lumen circumference of the aorta, measured in microns, was significantly 
different in the ENT1-/- 2064 ± 36 microns (N=6) when compared with the ENT1+/+ counterparts 
of 2320 ± 71 microns (N=6, **P<0.01). The carotid arteries were not significantly different in 
circumference with ENT1+/+ 1153 ± 19 microns (N=4) and ENT1-/- 1105 ± 51 microns (N=4, 
P<0.05). The decrease in lumen circumference was not expected however it does corroborate the 
findings of increased blood pressure. 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 3.3. Histological appearance of thoracic aorta (Panel A), and carotid arteries (Panel 
B) in 3 – 4 month-old ENT1+/+ and ENT1
arrangement were analyzed. Samples were sectioned in the transverse plane and s
haematoxylin and eosin (H&E). Images are 
– 4 months of age. Scale bars represent 100 
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Figure 3.4. Measurement of ENT1+/+ and ENT1-/- aortas and carotids looking at vascular 
wall thickness (Panel A) and lumen circumference (Panel B). Tissues were perfusion fixed 
with paraformaldehyde. Each point represents the mean ± SEM from six experiments in aortas 
and four experiments in carotids in ENT1+/+ and ENT1-/- mice. *Significant difference between 
circumference of ENT1+/+ and ENT1-/-. (Student’s t test for unpaired experimental parameters, 
**P<0.01) 
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3.4 Visualization of isolated tissues with Alizarin Red counterstained with Haematoxylin 
 Aortic ring slices from 3 – 4 month old male mice, stained with Alizarin Red and 
counterstained with Haematoxylin, did not appear significantly different from each other (Figure 
3.5). ENT1+/+ and ENT1-/- thoracic aorta (Panel A) were analyzed for calcification of the tissues 
to determine whether the mineralization phenotype previously described in Warraich et al. 
(2012) would not have an effect on vascular studies to be carried out in mouse line [32]. Positive 
and negative controls were used to ensure consistency of staining method (Panel B). Positive 
control shows bone from a post-natal mouse at day zero of development and negative control is a 
mouse heart at 3 – 4 months of age. The positive control has large areas of red which is the 
anthraquinone dye reacting with the calcium cations to form a chelate. The negative control, 
mouse heart, has very small amounts of red indicating lower levels of calcium. The areas of 
interest had no apparent calcium rich areas and a positive signal was not visualized. 
 
 
 
 
 
 
 
 Figure 3.5. Histological appearance of thoracic aorta (Panel A), and positive and negative 
controls (Panel B). Positive control is bone from a post
remainer are 3 – 4 month old mice
were sectioned in the transverse plane and stained with alizarin red and counterstained with 
alizarin red and counterstained with haematoxylin. Images are representative of 
each genotype at 3 – 4 months of age. Scale bars represent 100 
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3.5 Aortic vascular wall is stiffer in ENT1-/- than ENT1+/+ 
Length-tension curves were carried out in which 3 – 4 month old male mice vessels were 
stretched at intervals of 50 microns. There was a significant difference between ENT1+/+ and 
ENT1-/- mice in which the length-tension curves of ENT1-/- aortas are increased (Figure 3.6, 
Panel A, *P<0.05). No significant difference was seen in the ENT1-/- and ENT1+/+ carotid 
arteries (Figure 3.6, Panel B, P<0.05). The increase in vessel stiffness within the aorta was not 
expected but is consistent with the increased blood pressure observed in the conscious ENT1-/-. 
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Figure 3.6. Length-Tension curves of ENT1+/+ and ENT1-/- aorta (Panel A) and carotid 
arteries (Panel B). The effect of stretching vascular tissue in intervals of 50 microns on the 
tension generated in 3 – 4 month old mice. Tissues were incubated for 30 minutes at 22˚C in 
KPSS buffer with no resting tension. Each point represents the mean ± SEM from seven 
experiments on aortas (Panel A) and three experiments on carotid arteries (Panel B) in ENT1+/+ 
and ENT1-/- mice. *Significant difference between microns stretched and resultant tension in 
ENT1+/+ and ENT1-/- aorta. (Two-Way ANOVA for unpaired experimental parameters, 
***P<0.001)  
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3.6 Potassium Chloride induced depolarization resulted in significantly greater generated 
tension in ENT1-/- vascular tissues 
A number of vasoconstrictors were tested to determine if there were any tissue receptor 
specific differences or increased sensitivities in the aortas and carotid arteries between 
genotypes. Initial viability tests were done using 100 mM of KCl tested aortic rings at applied 
resting tensions of 500 mg, 750 mg and 1000 mg, and carotid arteries were tested at 500 mg of 
tension (Figure 3.7). In this model, when vascular rings were exposed to 100 mM KCl, a 
generated contraction of more than 200 mg was considered viable.  
The KCl induced depolarization was significantly higher in both the aortas and carotids 
of ENT1-/- mice. The aortas of 3 – 4 month old ENT1-/- mice resulted in vasoconstriction 
significantly more at 500 mg and 750 mg of resting tension, and were trending towards 
significance at 1000 mg of resting tension (P=0.062). The KCl-mediated vasoconstriction was 
significantly higher in the ENT1-/- mice at 750 mg and 1000 mg resting tension, and trending 
towards significance at 500 mg resting tension for the mice at 6 months of age (P=0.067). 
Vasoconstriction in the carotid arteries showed the same trend with increased tissue 
depolarization and greater generated contraction in the ENT1-/- mice (P<0.01). Increased tissue 
depolarization as a result of KCl is an entirely novel finding and was completely unexpected. 
To replicate the conditions seen in the ENT1-/- mice in the ENT1+/+ mice, aortic rings 
were incubated in 1 µM of NBMPR (the high affinity selective inhibitor of ENT1) following 
which 100 mM KCl was applied. As previously described, the control KCl treatment produced 
significantly greater vasoconstriction in ENT1-/- tissue than compared to the ENT1+/+ 
counterparts (P<0.05) but when incubated with NBMPR the ENT1+/+ tissues level of 
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depolarization remained consistent between control and experimental parameters whereas the 
ENT1-/- tissue trended (P=0.059) towards a large decrease in vasoconstriction (Figure 3.8). The 
contraction between ENT1-/- control and NBMPR test groups was not significant, neither was the 
difference between ENT1+/+ and ENT1-/- NBMPR treatment groups. We had expected to mimic 
the ENT1-/- response by inhibiting ENT1 with NBMPR, thus the change in ENT1-/- response in 
the presence of NBMPR was not expected. 
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Figure 3.7. Treatment of ENT1+/+ and ENT1-/- aortas and carotids with KCl. Effects of KCl 
on contraction by tissue depolarization in 3 – 4 month old mice (Panel A and Panel C) and 6 
month old mice (Panel B). Tissues were incubated for 30 minutes at 37˚C in KPSS buffer at 
resting tensions of 500 mg, 750 mg and 1000 mg. Following equilibration period, 100 mM KCl 
was administered to assess tissue viability. Each point represents the mean ± SEM from six 
experiments (Panel A), five experiments (Panel B) and 7 ENT1+/+ and 11 ENT1-/- (Panel C). 
*Significant difference in both age groups for KCl studies. (Student’s t test for paired 
experimental parameters,* P<0.05, **P<0.01)  
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Figure 3.8. KCl and NBMPR treatment of ENT1+/+ and ENT1-/- aortas. Effects of KCl on 
contraction by tissue depolarization in 3 – 4 month old mice and the effects of KCl (100 mM) on 
contraction when in the presence of: ENT1 blocker NBMPR (Panel A) or DMSO (Panel B). 
Tissues were incubated for 30 minutes at 37˚C in KPSS buffer at resting tensions of 500mg. 
Each point represents the mean ± SEM from seven experiments (KCl treated) and six 
experiments (KCl + NBMPR) in ENT1+/+ and ENT1-/- mice. *Significant difference between 
KCl ENT1+/+ and ENT1-/-. ENT1+/+ aortas were tested with DMSO (N=4) only to ensure the 
DMSO had no effect on the tissues. No significant difference was seen between the control and 
DMSO experimental group. (Student’s t test for paired experimental parameters, *P<0.05)  
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Receptor-mediated vasoconstrictors phenylephrine, PGF2α and serotonin were applied to 
aortic rings at resting tensions of 500 mg. In addition, the aorta was tested with 750 mg and 1000 
mg of resting tension with phenylephrine and the carotid arteries were tested with phenylephrine 
at resting tensions of 500 mg. The purpose of testing multiple vasoconstrictors was to establish a 
baseline receptor mediated contraction that could be compared across all future experiments. 
Establishment of the vasoconstrictor was essential to carry out the hypoxia experiments outlined 
in the objectives. All tests were carried out in 3 – 4 month old mice. Initial vasoconstriction 
testing with PGF2α (Figure 3.9, Panel A), serotonin (Figure 3.9, Panel B) and phenylephrine 
(Figure 3.9, Panel C) yielded no significant differences between the ENT1+/+  and ENT1-/- mice 
with serotonin EC50s 6.37x10-7  for ENT1+/+ and 5.80x10-7 for ENT1-/-, and phenylephrine EC50s 
9.07x10-8 for ENT1+/+ and 5.70x10-8 for ENT1-/-. A Vmax was not obtained for PGF2α therefore 
an EC50 could not be calculated. No significant difference was seen in the phenylephrine dose-
response on the carotid arteries (Figure 3.9, Panel D), with EC50 of 1.08x10-7 for ENT1+/+ and 
1.51x10-7 for ENT1-/-. The phenylephrine dose-response curves appeared to be trending towards 
a significant difference. To tease apart the results, a phenylephrine dose-response was carried out 
at 1000 mg of resting tension (Figure 3.10) and analyzed using a Two-Way ANOVA. 
Phenylephrine dose-response while at 1000 mg of resting tension yielded an EC50 of 5.67x10-8 in 
the ENT1+/+ and 1.49x10-8 in the ENT1-/- mouse. No significant difference was seen between the 
ENT1+/+ and ENT1-/- (N=3, P<0.05). The lack of significant differences between experimental 
groups is what was expected. 
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Figure 3.9. Dose-Response curves of ENT1+/+ and ENT1-/- aortas (Panels A, B and C) and 
carotid arteries (Panel D). Effects of PGF2α (Panel A), Serotonin (Panel B) and Phenylephrine 
(Panel C and D) on receptor mediated contraction in 3 – 4 month old mice. Tissues were 
incubated for 30 minutes at 37˚C in KPSS buffer at resting tensions of 500 mg after which they 
were depolarized with 100 mM KCl. Each point represents the mean ± SEM from five 
experiments (Panel A), three experiments (Panel B), six experiments (Panel C) and six 
experiments (Panel D) in ENT1+/+ and ENT1-/- mice. No significant difference between ENT1+/+ 
and ENT1-/-. (Two-Way ANOVA for paired experimental parameters, P<0.05)  
A  PGF2α B  Serotonin 
C  Phenylephrine D  Phenylephrine – Carotid Arteries 
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Figure 3.10. Dose-Response curve of ENT1+/+ and ENT1-/- aortas with 1000mg of resting 
tension applied. Phenylephrine on receptor mediated contraction in 3 – 4 month old mice. 
Tissues were incubated for 30 minutes at 37˚C in KPSS buffer at resting tensions of 1000mg 
after which they were depolarized with 100 mM KCl. Each point represents the mean ± SEM 
from three experiments in ENT1+/+ and ENT1-/- mice. *No significant difference between 
ENT1+/+ and ENT1-/-. (Two-Way ANOVA for unpaired experimental parameters, P<0.05)  
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3.7 ENT1-/- mice had variable response to hypoxic conditions when compared to ENT1+/+ 
In accordance with the outlined objectives, the ENT1-/- vasculature was compared to the 
ENT1+/+ under hypoxic conditions. Phenylephrine was applied to aortic rings at resting tensions 
of 500 mg (Figure 3.11). All tests were carried out in 3 – 4 month old mice. The mice were 
compared between genotypes under various conditions. As previously stated, under control 
conditions the phenylephrine dose-response yielded an EC50 of 9.07x10-8 (SEM=2.28x10-8) in 
the ENT1+/+ and EC50 of 5.70x10-8 (SEM=2.13x10-8) in the ENT1-/- mouse. Under hypoxia with 
no other experimental conditions, the EC50 was 7.97x10-8 (SEM=3.68x10-8) in the ENT1-/- and 
EC50 was 6.13x10-8 (SEM=1.97x10-8) in the ENT1+/+ mouse (Figure 3.11 Panel A and Table 
3.1). Treatment with adenosine at concentrations 10 µM, 30 µM, 100 µM and 300 µM, yielded 
EC50s of 1.41x10-8 (SEM=1.88x10-8), 3.62x10-8 (SEM=5.83x10-5), 3.53x10-8 (SEM=2.35x10-8), 
7.19x10-8 (SEM=2.91x10-8), respectively in the ENT1+/+ mice. These treatments were used as 
controls for the adenosine treated hypoxia experiments.  
Treatment with adenosine prior to hypoxia was carried out in both ENT1+/+ and ENT1-/- 
mice. All treatments were followed with a 30 minute normoxic period then a phenylephrine dose 
response. Ten µM concentrations of adenosine yielded EC50 values of 6.16x10-8 (SEM=8.30x10-
8) in the ENT1+/+ and 1.89x10-8 (SEM=9.80x10-9) in the ENT1-/-. At 30 µM, ENT1+/+ and ENT1-
/-
 yielded EC50 values of 1.17x10-7 (SEM=5.05x10-8) and 5.82x10-8 (SEM=2.68x10-8), 
respectively. One hundred µM and 300 µM concentrations of adenosine yielded EC50 values of 
7.38x10-8 (SEM=2.39x10-8) and 1.16x10-7 (SEM=3.08x10-8) in the ENT1+/+ and 6.05x10-8 
(SEM=5.29x10-8) and 7.38x10-9 (SEM=1.21x10-8) in the ENT1-/-respectively. The ENT1-/- aortic 
tissue had significantly less vasoreactivity at all concentrations of adenosine except for 100 µM. 
A significant difference was seen between the pretreatment with 30 µM (*P<0.05), 100 µM 
(*P<0.05) and 300 µM (***P<0.001) on ENT1+/+ and the pretreatment followed by hypoxia 
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ENT1+/+. The 100 µM concentration resulted in significantly smaller generated tension than the 
adenosine control whereas the 30 µM and 300 µM concentrations resulted in significantly more 
contraction in response to phenylephrine. Treatment with ENT1 blocker NBMPR prior to 
hypoxia yielded an EC50 of 1.72x10-8 (SEM=1.33x10-8) and treatment with NBMPR followed by 
300 µM adenosine and subsequently hypoxia, yielded an EC50 of 3.10x10-8 (SEM=9.14x10-9) 
within the ENT1+/+. Treatment with ENT1 blocker NBMPR prior to hypoxia on the ENT1-/- 
aortic tissue yielded an EC50 of 1.39x10-8 (SEM=9.30x10-8). The NBMPR alone compared to 
adenosine plus NBMPR resulted in a significantly lower dose-response (***P<0.001) in the 
ENT1+/+. Between genotypes, the ENT1-/- also generated diminished contraction when compared 
to the ENT1+/+ (**P<0.01). The diminished response in the ENT1-/- was not expected as previous 
evidence has shown ENT1-/- mice to be cardioprotected. 
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Table 3.1. Phenylephrine Dose-Response EC50s of ENT1+/+ and ENT1-/- aortas under 
different experimental conditions. Effects of an hour of hypoxia on aortic tissue after pre-
treatment with increasing doses of Adenosine (10 – 300 µM) and NBMPR (1 µM), on 
phenylephrine induced contraction (1 nM – 30 µM). 
Treatment Genotype EC50  SEM Tmax (%) 
Control +/+ 9.07x10-8  2.28x10-8 49.0 
 
-/- 5.70x10-8  2.13x10-8 38.4 
 
 
    
Hypoxia +/+ 6.13x10-8  1.97x10-8 43.9 
 
-/- 
    7.97x10-8**  3.68x10-8 32.5 
 
 
    
Control + 10 µM Adenosine +/+ 1.41x10-8  1.88x10-8 39.6 
Control + 30 µM Adenosine +/+ 3.62x10-8  5.83x10-5 31.2 
Control + 100 µM Adenosine +/+ 3.53x10-8  2.35x10-8 41.1 
Control + 300 µM Adenosine +/+ 7.19x10-8  2.91x10-8 45.6 
 
 
    
10 µM Adenosine + Hypoxia +/+ 6.16x10-8  8.30x10-8 49.9 
 
-/- 
      1.89x10-8***  9.80x10-9 27.7 
 
 
    
30 µM Adenosine + Hypoxia +/+   1.17x10-7*  5.05x10-8 61.2 
 
-/- 
    5.82x10-8**  2.68x10-8 40.2 
 
 
    
100 µM Adenosine + Hypoxia +/+   7.38x10-8*  2.39x10-8 36.4 
 
-/- 6.05x10-8  5.29x10-8 43.7 
 
 
    
300 µM Adenosine + Hypoxia +/+      1.16x10-7***  3.08x10-8 65.8 
 
-/- 
   7.38x10-9**  1.21x10-8 20.4 
 
 
    
 
 
    
NBMPR + Hypoxia +/+      1.72x10-8***  1.33x10-8 44.3 
 
-/- 
   1.39x10-8**  9.30x10-8 29.6 
 
 
    
NBMPR + 300 µM Adenosine + 
Hypoxia 
+/+ 3.10x10-8  9.14x10-9 67.7 
 
 
    
*Tmax(%) = maximum tension developed, expressed as a percentage of the pretreatment of 100 
mM KCl. Values are a mean ± SEM of N=6 for control, N=6 for hypoxia, N=3 for 10 µM, 100 
µM and 300 µM Adenosine controls (30 µM Adenosine with Control is only N=2), N=4 for 10 
µM, 30 µM, 100 µM and 300 µM Adenosine in Hypoxia, N= 4 for NBMPR in hypoxia and N=4 
for NBMPR + 300 µM Adenosine in hypoxia. Note: (*) indicates significance between 
treatments within the ENT1+/+ genotype. (Two-Way ANOVA for unpaired experimental 
parameters, *P<0.05, **P<0.01, ***P<0.001). 
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Figure 3.11. Phenylephrine Dose-Response Curves following Hypoxia. Normoxia vs. 
Hypoxia (Panel A), 10 µM adenosine experiments (Panel B), 30 µM adenosine experiments 
(Panel C), 100 µM adenosine experiments (Panel D), 300 µM adenosine experiments (Panel E), 
NBMPR with and without 300 µM adenosine experiments (Panel F). Tissues were incubated for 
30 minutes at 37˚C in KPSS buffer at resting tensions of 500 mg after which they were 
depolarized with 100 mM KCl. Hypoxic conditions were introduced to the organ bath on all 
experimental groups except for control and lasted 60 minutes. In treatment groups with 
Adenosine, treatment was administered 30 minutes before hypoxic period. Groups treated with 
NBMPR were administered 15 minutes prior to either adenosine treatment or hypoxia. Each 
point represents the mean ± SEM with N=6 for control, N=6 for hypoxia, N=4 for 10 µM, 30 
µM, 100 µM and 300 µM Adenosine in Hypoxia, N= 4 for NBMPR in hypoxia and N=4 for 
NBMPR + 300 µM Adenosine in hypoxia.*Significant difference between genotypes. Note: (*) 
indicates significance between treatments within the ENT1+/+ genotype. (Two-Way ANOVA for 
unpaired experimental parameters, *P<0.05, **P<0.01, ***P<0.001). 
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PGF2α was then used to test whether there was a release of adenosine from the aorta and carotid 
arteries during the hypoxic event allowing us to examine the vascular tissue as it responded to 
hypoxic conditions (Figure 3.13) . The ENT1+/+ and ENT1-/- vessels were vasoconstricted within 
PGF2α at 80% maximal and allowed to plateau. Tissues were then exposed to one hour of 
hypoxia. The initial plateau period prior to hypoxia was then compared to the final generated 
contraction. The aortas measured a contraction of 99.4 ± 20.8 mg in the ENT1+/+ and 115.2 ± 9.8 
mg in the ENT1-/-(N=6).The carotid arteries measured a contraction of 110.2 ± 18.2 mg in the 
ENT1+/+ and 75.1 ± 12.1 mg in the ENT1-/-(N=5). Neither the aortas (Figure 3.13, Panel A) nor 
the carotids (Figure 3.13, Panel B) had significantly different levels of vasodilation following the 
hypoxic challenge (P<0.05).  
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Figure 3.12. Phenylephrine Dose-Response Curves of ENT1+/+ and ENT1-/- in carotid 
arteries under hypoxic conditions. Tissues were incubated for 30 minutes at 37˚C in KPSS 
buffer at resting tensions of 500mg after which they were depolarized with 100mM KCl. 
Hypoxic conditions were introduced to the organ bath and lasted 60 minutes. Afterwards, tissues 
were then incubated in normoxic conditions for 30 minutes followed by a phenylephrine dose-
response. Each point represents the mean ± SEM with N=6. No Significant difference between 
treatment groups. (Two-Way ANOVA for unpaired experimental parameters, *P<0.05) 
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Figure 3.13. Hypoxia induced vasodilation in ENT1+/+ and ENT1-/- aortas (Panel A) and 
carotid arteries (Panel B) after preconstriction with 80% of maximum PGF2α.  Tissues 
were incubated for 30 minutes at 37˚C in KPSS buffer at resting tensions of 500 mg after which 
they were depolarized with 100 mM KCl to test for viability. Results were then normalized to 
PGF2α and converted to a percentage. Each point represents the mean ± SEM from six 
experiments (Panel A) and five experiments (Panel B). (Student’s t test for unpaired 
experimental parameters, *P<0.05) 
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3.8 Vasodilatory effects variable between ENT1+/+ and ENT1-/- mice 
Three – four month old male mice were compared between genotypes to identify the 
effects seen between the ENT1+/+ and ENT1-/- when adenosine is applied in increasing 
concentrations alone and in the presence of the A2A blocker SCH58261. The vasodilation 
measured in the aorta during the experiments with only adenosine (Figure 3.14, Panel A) showed 
a significantly greater response in the ENT1-/-
 
(***P<0.001, N=5) when compared to the 
ENT1+/+ vessel. The carotid arteries did not however show any significant difference in 
vasodilation between genotypes (N=5, Figure 3.8, Panel B). Ten µM methacholine was used to 
ensure the endothelium was still intact. No significant difference was seen between ENT1+/+ and 
ENT1-/- in either aorta or carotid arteries (Figure 3.14, Panel C) (P<0.05). The A2A blocker 
SCH58261 also yielded no significant difference between the ENT1+/+ and ENT1-/- 3 – 4 month 
old mice in either the aortas (N=15, Figure 3.10, Panel A) and carotid arteries (N=4, Figure 3.15, 
Panel B). The resultant increase in adenosine vasodilation in the absence of SCH58261 was what 
was expected with the loss of ENT1. 
 
 
 
 
 
 
 
 
 
74 
 
 
 
 
-7 -6 -5 -4 -3 -2
0
25
75
100
125
***
Log [Adenosine]
Te
n
si
o
n
 
(m
g)
N
o
rm
al
iz
ed
 
to
 
 
PG
F2
αα αα
 
-
9
-
8
-
7
-
6
-
5
-
4
-
3
-
2
0
25
50
75
100
125
150
175
ENT1+/+
ENT1-/-
Log [Adenosine]
Te
n
si
o
n
 
(m
g)
No
rm
al
iz
ed
 
to
 
 
PG
F2
αα αα
 
0
20
40
60
80
100
ENT1-/-
ENT1+/+
I I
Te
n
si
o
n
 
(m
g)
No
rm
al
iz
ed
 
to
 
 
PG
F2
αα αα
 
 
Figure 3.14. Dose-Response of adenosine in ENT1+/+ and ENT1-/- aortas (Panel A) and 
carotid arteries (Panel B) analyzing vasodilatory effects after preconstriction with 80% of 
maximum PGF2α.  Presence of endothelium was established via a 10 µM methacholine dose in 
ENT1+/+ and ENT1-/- aortas and carotid arteries (Panel C) after preconstriction with 80% of 
maximum PGF2α. Tissues were incubated for 30 minutes at 37˚C in KPSS buffer at resting 
tensions of 500 mg after which they were depolarized with 100 mM KCl to test for viability. 
Results were then normalized to PGF2α and converted to a percentage. Each point represents the 
mean ± SEM from five experiments Panel A and B are six experiments in arotas, five 
experiments in ENT1+/+ and four experiments in ENT1-/- carotid arteries (Panel C). *Significant 
difference between vasodilation of ENT1+/+ and ENT1-/- aortas. (Student’s t-test for unpaired 
experimental parameters, Two-Way ANOVA for unpaired experimental parameters, 
***P<0.001) 
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Figure 3.15. Dose-Response of adenosine in ENT1+/+ and ENT1-/- aortas (Panel A) and 
carotid arteries (Panel B). Vasodilation as a result of adenosine was measured after tissue 
was pre-incubated with 0.1uM of A2A blocker SCH58261 for 15 minutes and pre-
constriction with 80% of maximum PGF2α.  Tissues were incubated for 30 minutes at 37˚C in 
KPSS buffer at resting tensions of 500 mg after which they were depolarized with 100 mM KCl 
to test for viability. Results were then normalized to the PGF2α maximum tension generated and 
converted to a percentage. Each point represents the mean ± SEM from four experiments in 
aortas (Panel A), three experiments in carotid arteries (Panel B).  (Two-Way ANOVA for 
unpaired experimental parameters, P<0.05) 
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3.9 Expression of target genes Ada, Ak and Catalase, in the descending thoracic aorta found 
no significant differences between genotypes 
 Gene expression was important to understand what was changing on a molecular scale 
and to directly examine the hypothesis and understand what is being disrupted in the normal 
purinergic homeostatic mechanism. Gene expression data were not significantly different 
between genotypes for catalase, Ak or Ada in 3 – 4 month old mice. The ENT1+/+ and ENT1-/- 
aorta expression data were calculated relative to beta actin expression (beta actin was within 1 ct 
value). Ada expression in ENT1+/+ was 1.01 ± 0.12 (N=3) and ENT1-/- was 1.01 ± 0.12 (N=3). Ak 
expression in ENT1+/+ was 1.12 ± 0.32 (N=3) and ENT1-/- was 1.03 ± 0.19 (N=3). Catalase 
expression in ENT1+/+ was 1.04 ± 0.20 (N=3) and ENT1-/- was 1.05 ± 0.23 (N=3). ENT1 
expression was not present in the ENT1-/- which was not surprising and within the ENT1+/+ was 
0.96 ± 0.48 (N=5). 
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Figure 3.16. Relative Gene Expression of ENT1+/+ and ENT1-/- aortas. Results were 
normalized to Beta Actin. Each point represents the mean ± SEM from three experiments (Panel 
A – C) and five experiments (Panel D). (Student’s t-test for unpaired experimental parameters) 
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Cardioprotection via purinergic signaling has been examined extensively across many 
animal models. Studies examining the effects of ecto-5ʹ-nucleotidase (CD73) and 
ectonucleoside triphosphate diphosphohydrolase 1 (CD39) on extracellular adenosine production 
and signaling; and subsequent cardioprotection via ischemic pre-conditioning are well 
documented [54]. The goal of the current study was to establish a link between adenosine 
transport across cell membranes and vascular protection. 
Prior to this thesis, there has been work done within the ENT1-null mouse model 
designed by Choi et al. (2004) [29]. This mouse model has made research on cardiac tissues, 
analysis of the spine and skeletal phenotype and a look at neurophysiology possible within a full 
body knock-out. The mouse line was initially characterized to assess the role of adenosine 
transport within the central nervous system [29], particularly looking at behavioural aspects and 
analyzing the ENT1-/-
 
propensity for greater ethanol consumption. The observed behaviour was 
linked to the decrease of A1 receptor stimulation presumably due to reduced extracellular 
adenosine. Work done within the Hammond laboratory by Warraich et al. (2012) found evidence 
of calcified lesion within the spinal tissue of the ENT1-/-, a phenotype which may be linked to 
diffuse idiopathic skeletal hypertosis (DISH) in humans [32]. As yet, this finding remains 
relatively new and DISH patients have not been examined for mutations in ENT1. This finding 
led to a preliminary investigation of the vasculature, looking for evidence of calcium deposits 
although no evidence of increased cardiovascular disease has been witnessed in subjects with 
DISH. 
Other work within the Hammond laboratory has been done using microvascular 
endothelial cells from the ENT1-/- mouse to assess the mechanisms of transport and how 
nucleosides and nucleobases are metabolized [31]. It was found that there was no change in the 
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ENT2 or equilibrative nucleobase transporter subtype 1 (ENBT1) expression in cells from ENT1-
/-
 mice [57].  However, an increase in adenosine deaminase (ADA) and adenosine A2A receptors 
was observed in the ENT1-/- cells when compared to the wild type, indicating an adaptive 
response due to loss of the transporter [31].  
Collaborators at York University found evidence of cardioprotection within this null 
mouse model when examining infarct size differences between the ENT1-/- and their wild type 
counterparts. The wild type possessed a larger infarct area following an hypoxic challenge, 
which further fueled an interest in examining the vascular protective properties of ENT1 loss or 
inhibition [33]. 
The inability of the ENT1-/- mouse tissue to release adenosine through the transporter 
may lead to generation of reactive oxygen species (ROS) through the enhanced intracellular 
metabolism of adenosine. The increased activation of ADA results in inosine production and 
stimulation of the xanthine oxidase pathway (Figure 4.1).  
4.1 ENT1-/- mouse vasculature has morphological and phenotypic differences 
To assess whether the disruption of the transporter had any morphological effects on the 
vasculature, paraformaldehyde was used to fix the aorta and carotids of 3 – 4 month old male 
mice and stained with haematoxylin and eosin (H&E) as well as alizarin red counterstained with 
haematoxylin (Figure 3.3, Figure 3.5), to visualize the structure and to determine whether 
calcium was present in any quantities within the vascular tissues.  
H&E is a stain in which the haematoxylin is used to stain acidic structures such as the 
nuclei of cells, as the dye itself is basic, while eosin, which is an acidic dye, stains the basic 
structures which include the cytoplasm, collagen, and muscle fibers. Alazarin Red uses an 
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anthraquinone dye to react with calcium cations to form a chelate. Counterstain of haematoxylin 
was used to provide contrast to any visualized red. It has been observed that ENT1 has a role in 
the regulation of soft tissue calcification as observed in the ENT1-/- mice [32]. 
 
 
 
 
 
 
 
 
 
 Figure 4.1 Adenosine deaminase and xanthine oxidase pathway.
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The examination of the vertebral discs found that an above average amount of 
mineralization was occurring at 6 – 8 weeks of age in the ENT1-/- male mice. Therefore, to 
ensure the calcification discovered previously in this mouse model was localized to the vertebral 
discs, the present study using Alizarin Red was carried out on the vasculature of the aorta. 
Previous studies had found that aberrant mineralization occurred within 6 – 8 weeks of age 
however the aortas were negative for alizarin red staining which suggests that calcium is not 
present within the vasculature at 3 – 4 months of age. Finding calcium within the vasculature 
would have been entirely novel, and any findings alluding to its presence would impact all 
studies done within the vasculature in this line of mice. Typically, arterial calcification involves 
the accumulation of calcium phosphate crystals within the arterial walls. The presence of 
calcification in the medial layer is known as Monkeberg’s sclerosis; a form of atherosclerosis. 
An underlying disease state in the vasculature of the ENT1-/- model such as atherosclerosis 
would have widespread consequences on the vascular studies [58].  
The staining of the aorta and carotid arteries with H&E yielded no apparent changes in 
nuclei organization nor did the amount of elastic fiber layers indicate any gross morphological 
changes. More or fewer nuclei could indicate a greater or lesser degree of cell replication which 
in turn could affect cell ATP production, enzyme modulation and protein synthesis. The presence 
of more, or degraded and fragmented elastic fibers could have an equally varied effect. During 
the cardiac cycle the elastin provides reversible extension and having more or less would affect 
the ability of the vasculature to expand or contract.  Elastic lamellae in unloaded arteries appear 
wavy as opposed to when they are under pressure, at which point they are straightened [59]. 
Tissues were excised under pressure, using gravity perfusion, to mimic the appearance under 
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physiological conditions. With increased elastic capabilities due the requirement of pumping 
blood throughout the body, it is not surprising that arteries have more elastic fibers than veins.  
In studying arterial stiffness by stretching the aorta and carotid arteries, while measuring 
tension, we observed stiffening within the aorta of ENT1-/- mouse walls (Figure 3.6) although 
none was seen in the carotid arteries.  This could imply the beginnings of arterial damage that 
has not yet reached the peripheral arteries in its progression. Arterial stiffness is an important 
precursor to cardiac mortality. Increased vascular stiffness is found in patients with hypertension 
as well as a score of other diseases and this increased stiffness is the beginning of an increased 
mechanical load on the heart [60,61]. 
Further analysis of the vascular tissues found that the lumen circumference in the ENT1-/- 
had an approximate decrease of 11% however wall thickness was unchanged. The narrowing of 
the lumen can have many implications on the overall flow rate of the system, including 
increasing the velocity of the flow as well as the pressure. A decrease in lumen circumference 
will result in a decrease in the volume flow rate. The increase in pressure that results from a 
smaller lumen in an artery, especially within a major artery as the aorta is significant because it 
places an increased load on the heart requiring the heart to pump harder to increase the pressure 
of the circulating blood, in order to maintain sufficient blood flow to the peripheral vasculature 
and the tissues they supply. Blood pressure analysis of the mice in a conscious state (Figure 3.2) 
were consistent with these findings and confirmed that there is an increase in systolic, diastolic 
and mean arterial pressures. 
Elevation of the blood pressure puts a strain on the heart affecting cardiovascular health.  
Chronic elevation of the blood pressure is a disease of the heart, termed hypertension. High 
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arterial blood pressure can lead to a shortened life span or death from myocardial infraction or 
stroke, whereas mild increases may have no lasting effects on cardiovascular health [62].  Due to 
previous studies done by Chen et al. (2007) in which the activation of adenosine receptors in the 
brain, linked to the loss of ENT1 and the ability to transport adenosine into and out of the cell 
resulting in anxiolytic phenotype,  it was thought that blood pressure would in fact decrease 
[30,63,64]. However a review of anxiety and cardiovascular disease was published in which a 
comparison of various studies done across the world found instances in which higher levels of 
anxiety symptoms were associated with lower blood pressure, and studies in which high anxiety 
did not lead to any increased risk of hypertension [65,62].  Further, the mice were examined 
while they were anaesthetized with isoflurane and no differences were found between the ENT1-
/-
 and ENT1+/+. It is important to note that, while the mice were anaesthetized, the mean arterial 
pressure dropped significantly in both genotypes with a 28% decrease in the ENT1+/+ and a 37% 
decrease in the ENT1-/- mice.  
Decreases in blood pressure while sleeping are known as nocturnal dipping. These 
changes occur normally and are associated with a decrease in sympathetic output. The 
sympathetic nervous system (SNS) is responsible for the fight-or-flight response in which there 
is a release of adrenal catecholamines [66]. A decrease in sympathetic output, that is greater in 
the ENT1-/-, suggests a difference between sympathetic regulation. Release of epinephrine or 
norepinephrine, or differential abundance of adrenergic receptors can result in variations in 
sympathetic output between genotypes. Any changes among the three alpha1-, three alpha2- or 
three beta-receptors could potentially result in the differences observed. In the context of this 
study, the SNS impacts heart rate acceleration, capacity and resistance of peripheral vessels and 
contractility [67]. In a heart failure model, the SNS is activated to restore cardiac output. This 
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mechanism is explained via the stimulation of pacemaker cells, the cells that create the rhythmic 
electrical impulses that innervate the heart, by the sympathetic nervous system. Endocrines such 
as norepinephrine and epinephrine increase the ion flow rate through channels. Increased cation 
entry increases the rate of pacemaker cell depolarization leading to a downstream effect of 
increased attainment of threshold levels and subsequent action potential firing. Increased action 
potential firing leads to increased heart rate. Heart rate measurements yielded no change between 
genotypes. Beyond the expected decrease while anaesthetized, no obvious sign of impairment or 
increased cardiac output was observed. Trends towards higher heart rate in the ENT1-/- were 
apparent but not statistically significant. 
We observed that the ENT1-/- mice being studied possessed smaller body weights than 
ENT1+/+ mice which is consistent with previous work done by Choi et al. (2004) in which a 
difference of 8.7% was seen in ENT1-/- mice aged 10 – 12 weeks [30]. In the present study, mice 
were 12 – 19 weeks old (3 – 4 months of age) and the difference between genotypes became 
even more significant at 13.6%. We then sought to explain this further by analysis of other 
metabolic factors.  
Analysis of food consumed did not yield any significant differences indicating that under-
eating is not a factor in apparent weight changes; however water consumption during active 
hours was higher in the ENT1-/-
 
mice. We did find that during the active hours, an increased 
amount of ambulatory and total movement over a 12 hour period of time was present. The higher 
levels of activity seen in the ENT1-/- mice could account for the leaner bodies; however on closer 
examination we found that this may only be one contributing factor. The fasting respiratory 
exchange ratio of the ENT1-/- mouse was lower than that of the ENT1+/+ indicating a propensity 
for more fat oxidation than carbohydrate. This trend was only witnessed in mice during the light 
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cycle, indicating that this state occurs during inactivity. During periods of high activity, 
respiratory exchange ratios between genotype were similar and closer to carbohydrate oxidation. 
Further analysis found that energy expenditure, also during fasting periods was lower, in the 
ENT1-/- mice. It is important to note that the ratio of brown to white fat is unknown within this 
mouse type and it is possible that a difference in fat storage may be present between genotypes. 
A study done in 1991 (Zurlo et al.) found that increased body weight was associated with 
an increased respiratory exchange ratio; and this finding was considered independent of any 
energy expenditure, although another study published in 1992 (Seidell et al.) claims that both an 
increase in respiratory exchange ratio and a decrease in energy expenditure are predictive factors 
of weight gain [68,69]. Inability of the cells to transport adenosine into the cells would lead to 
increased fat oxidation in an attempt by the cell to increase ATP stores. Extracellular adenosine 
is transported into the cells to undergo ATP production. Without adenosine being replenished the 
cells may experience energy (ATP) deprivation and begin removing ATP from stored deposits, 
depleting the liver, fat and muscle tissues.    
4.2 Assessment of potassium mediated depolarization 
Potassium chloride was initially used as a means of testing tissue viability within the aorta and 
carotid arteries. The mode of action of KCl involves the establishment of a resting membrane 
potential due to a diffusion potential of potassium across the membrane thus resulting in smooth 
muscle contraction. Upon testing for viability within the tissue, we noticed that the ENT1-/-
 
mice 
were producing a considerably higher degree of contraction when compared to the ENT1+/+ mice 
(Figure 3.7) in both aorta and carotid arteries. This was analyzed at various resting tensions in 
the aorta and was not found to be significant at all tensions. Those that were not significant were 
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trending towards this same effect. This was a novel observation and we hypothesized that the 
depolarization of the tissue simulated distress resulting in the ENT1+/+ tissue releasing adenosine 
from the cell, whereas the tissue was unable to release adenosine in the ENT1-/- due to the lack of 
transporter. ATP and adenosine are often characterized as distress signals and under specific 
circumstances, most notably necrotic cell death, there is a release of cellular adenine nucleotides 
resulting in an increase in adenosine stores [6]. The adenosine that is released in the ENT1+/+ 
mice is able to act on the adenosine receptors causing a vasodilatory effect that is not seen in the 
ENT1-/-.  However when we tested this theory in the aorta using the selective ENT1 blocker 
NBMPR (Figure 3.8), rather than mimicking the effects seen in the experimental group, the 
ENT1-/- aortas responded much like the ENT1+/+. In the presence of NBMPR the generated 
contraction as a result of KCl depolarization was 29% lower in the ENT1-/- than that of the 
contraction that was generated previously. The ENT1+/+ also decreased by 20% in the presence of 
NBMPR. Neither experiment was significantly different from the KCl in the absence of inhibitor 
experiment, however, neither were they significantly different between genotypes following 
NBMPR treatment. 
To ensure that the solvent, dimethyl sulfoxide (DMSO), in which the NBMPR was 
dissolved did not affect our results, the effects were tested on the ENT1+/+ aortas and we found 
no significant effect.  This result has led us to the prediction that it is not simply the lack of 
ENT1 that has resulted in the increased depolarization seen in these tissues but a byproduct of 
ENT1 removal through growth and development. We hypothesized that NBMPR at this 
concentration may be exhibiting a toxic effect on the ENT1-/- that we are not observing in the 
ENT1+/+, once again as a result of long term ENT1 deficits. It is also possible that ENT1-/- now 
exhibits an alternate transporter that is affected by NBMPR. Unfortunately the hypothesis 
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regarding toxicity is not corroborated by the literature, and studies in which 100 µM of NBMPR 
was utilized to incubate human fibroblast cells, the NBMPR was found to be non-toxic [70]. It 
was then suggested that the increased arterial stiffening may account for this increased response; 
however there is little evidence to support this as well. This increased susceptibility to potassium 
chloride is a novel finding thus it follows that further experiments will be required to elucidate 
the cause.  
4.3 Assessment of vasoreactivity to various receptor mediated agonists 
To determine if any receptor mediated vasoconstriction or vasodilation differences were 
present in the aorta, and to find a vasoconstrictor to use for subsequent vasodilation and hypoxia 
studies, multiple agonists were used. The characteristics we sought for the ideal vasoconstrictor 
were a strong generated contraction that was able to plateau and remain stable. The chosen 
agonists are the most widely used in vascular tissue studies and allowed us to use other models 
as a benchmark by which to set up our experimental protocols.  
Initially, examination of receptor mediated vasoconstriction was done with phenylephrine 
with the result of no significant difference between the ENT+/+ and ENT1 -/- mouse (Figure 3.9). 
The initial curves suggested trending towards significance.   To further elucidate this trend, 
additional experiments at a resting tension of 1000 mg were carried out (Figure 3.10). The 
results, however, did not show any further trend at this tension. The phenylephrine mechanism of 
action utilizes α1-adrenergic receptor signaling which is part of the G-protein coupled receptor 
superfamily. Phospholipase C activation increases inositol triphosphate resulting in an 
interaction with the calcium channels of the sarcoplasmic reticulum and increased Ca2+ within 
the cell. There have been numerous studies in which α1-adrenergic receptor agonists have been 
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tested for receptor desensitization. Decreased response to phenylephrine, and, in fact a large 
number of vasopressors has been reported in deep vessel tissue studies in which numerous 
animal models were subjected to moderate and extreme hypothermia. Studies have also been 
conducted in which the interaction of β-Arrestin 1 with G-protein coupled receptors can have a 
desensitizing effect, and recently in cirrihosis patients and rats this interaction was found to have 
direct bearings on the Gαs protein [71,72].  Therefore, it can be suggested that such an interaction 
may largely impact Gαq as well, although at the point of this paper, this question has yet to be 
answered as the dual functions of β-Arrestin and how they interact when all occur 
simultaneously, is still relatively unknown. 
Since phenylephrine did not provide us with a satisfactory result, we next examined 
serotonin which acts on 5HT2 (5-hydroxytryptamine) type receptors [73]. Because 5HT2 
receptors within the aorta are believed to up-regulate transforming growth factor (TGF)-β1 
expression and the activity of phospholipase C (PLC), serotonin was a good potential constrictor 
for this project [74]. Phospholipase C catalyses the synthesis of inositol trisphophate (IP3) 
(diacyglycerol), subsequently causing an increase in Ca2+ cytoplasmic concentrations as well as 
protein kinase C activation and substrate phosphorylation [75]. The contraction is caused by a 
release of Ca2+ from the sarcoplasmic reticulum. Ca2+ binds to calmodulin activating the myosin 
light chain kinase (MLCK) which phosphorylates myosin light chains with ATP. Cross-bridges 
are formed between myosin heads and actin filaments with this phosphorylation and the muscle 
contracts. The serotonin response was not maintained long enough between doses to confidently 
assess a dose-response and would not be useful for sustained generation of contraction to carry 
out a vasodilation dose-response. 
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Finally, PGF2α acts on the Prostaglandin F (FP) receptor stimulating Gαq and the 
hydrolysis and mobilization of inositol phospholipid hydrolysis leading to an increase in Ca2+. 
The study by Davis et al. (1987) also confirmed that PGF2α induces rapid and concentration-
dependent increases in Ca2+ that reach maximum within a 30 second time frame and maintained 
the contraction for a period of 8-10 minutes [76].  
The results in the experiments dealing with phenylephrine, PGF2α and serotonin did not 
result in a significant difference in contraction between the ENT1+/+ and ENT1-/- mice, however, 
they allowed me to characterize the ENT1-/- model further. We used PGF2α as a pre-constrictor 
for the subsequent adenosine vasodilation studies, as it maintains the most stable contraction of 
the three agonists I examined.  Furthermore, in order to examine the validity of the ENT1-/- 
model by examining the ability of adenosine to relax the vascular tissue in the aorta and carotid 
artery, vasodilation studies in the presence and absence of A2A blocker SCH58261 were 
undertaken.   
With the loss of ENT1 it is suggested that the exogenous adenosine that is no longer able 
to be transported into the cells will now be free to act on adenosine receptors on the cell surface. 
Before testing with adenosine, methacholine was used to ensure that the endothelium was still 
intact as it is an endothelium dependent vasodilator, and is indicated by a tissue relaxation 
(Figure 3.15). Methacholine acts on the muscarinic receptors to stimulate nitric oxide synthesis 
and subsequent vasodilation.  An intact endothelium is important to the vasodilation response. 
Downstream effects of adenosine receptor stimulation, as discussed previously, work in 
conjunction with cAMP and subsequent synthesis of nitric oxide by NOS, found within the 
endothelium.  The endothelial layer must therefore be intact to elicit the entire vasodilation 
response [43].   
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Multiple studies have examined the distribution of adenosine receptors in the vasculature, 
particularly in the aorta and found that across most species the dominant form is the A2A, and 
also present although at a lesser extent are the A2B receptors. As previously mentioned, both 
receptors lead to a subsequent vasodilation within the tissue and it is this response that we are 
interested in characterizing; the difference in ENT1 expression effects on the receptor 
stimulation within the vasculature.  
Using PGF2α as a pre-constricting agonist, a dose-response curve was carried out with 
adenosine and from the results, a clear vasodilation can be seen (Figure 3.15) that exceeds that of 
the ENT1+/+, thus indicating an increase in receptor activation in the ENT1-/- aorta. The increase 
in extracellular adenosine due to the tissue’s inability to transport the nucleoside results in the 
increased vasodilation that is observed in the ENT1-/- mice. Within the carotid arteries, the same 
phenomenon was not observed and could suggest differential distribution of the adenosine 
receptor subtypes. As not much is known of the level of receptor expression in the carotid 
arteries of mice, it is possible that a lesser amount of adenosine receptors are present overall and 
that at even low doses of adenosine, the receptors are saturated. Studies done by Li et al. (1998) 
utilizing endothelial cells from a human iliac artery and a porcine carotid artery found evidence 
of adenosine A2A receptor stimulation and a marked increase of NO production as well as A1 
receptor stimulation which elicited a decrease in NO production so there is at least some level of 
vaso-regulation present [77]. Herlihy et al. (1976) also carried out vasodilation studies on 
vascular smooth muscle cells of hogs and dogs and adenosine application resulted in vasodilation 
[13]. 
Following the verification of a significantly higher degree of adenosine relaxation in the 
ENT1-/- aortas, we then sought to block the effects of the A2A receptor using selective blocker 
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SCH58261. The higher degree of vasodilation observed in the ENT1-/- suggests a larger quantity 
of adenosine is acting on the adenosine receptors. This occurs because the tissue is unable to 
transport the adenosine from the extracellular into the cell of the ENT1-/-. Our goal was to 
evaluate our theory that this vasodilation was via A2A receptor activation by using A2A blocker 
SCH58261. Minimal vasodilation was observed between genotypes, which contrasts what was 
seen in the previous study. This suggests that the A2A receptor is indeed responsible for 
adenosine mediated vasodilation in the aortas. Similarly, the carotid artery dilation was reduced 
with the SCH58261 treatment suggesting that at least some of the receptors in the carotid arteries 
responsible for vasodilation when adenosine is administered are the A2A receptors. This 
corresponds with the previously mentioned study completed on human and porcine carotid artery 
endothelial cells [77]. 
4.4 Assessment of vasoreactivity under test conditions of hypoxia in aorta and carotid 
arteries 
Adenosine has been linked to cardioprotection as previously described, and furthermore, 
these mice have been studied extensively to examine the effects within the heart. To determine if 
the loss of ENT1 would attenuate damage when dealing with hypoxia in the vasculature to an 
increased degree than what is observed in the ENT1+/+ as a result of higher levels of adenosine to 
act within the tissue, we exposed the tissues to periods of hypoxia within an organ bath.  As 
previously discussed, hypoxic conditions along with mechanical and biochemical stimuli induce 
endothelium-derived relaxing factor (EDRF): NO.  Adenosine receptor stimulation results in a 
downstream signaling cascade of cAMP and adenylate cyclase activating NOS.  
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Our studies with hypoxia involved analyzing vasoreactivity under various conditions 
including preconditioning with adenosine and in the presence of ENT1 inhibitor NBMPR. The 
goal was to measure the ability of the tissue to contract following the hypoxic challenge. For 
purposes of measuring vasoreactivity, phenylephrine was the agonist of choice as our previous 
studies with it proved to elicit a contraction that was not significantly different across genotypes; 
accordingly it would provide a valid baseline from which to establish experimental parameters.  
The expectation was that in the ENT1-/-
 
tissues, hypoxia would have less of a detrimental 
effect as evidenced by a smaller decrease in vasoreactivity when compared to the ENT1+/+ group. 
The basis of this hypothesis is once again predicated on loss of ENT1 leading to an increase in 
adenosine mediated activation within the endothelium as there would be an increased quantity of 
adenosine in the extracellular space, resulting in purinergic signaling activation to increase cell 
survival, in other words preconditioning [52,78]. Our findings however do not support this 
hypothesis. What we found instead was that there was no significant difference in the hypoxic 
tissue when compared to the controls in either genotype which indicated that the hour of hypoxia 
was not a long enough period of oxygen deprivation to enlist permanent damage to the aortas or 
the carotids. Andresen et al. (2004) and Kim et al. (1993) used hypoxic periods of 30 minutes 
while in 1996, Kim et al. increased hypoxic period to 180 minutes [79,80,81](figure 3.11).  
In previous studies in which cardiac tissue was exposed to hypoxic conditions, the 
importance of ENT1 in the cardioprotection of the whole heart against ischemia was verified 
[33]. However, the present study was not able to recreate these findings in the aorta model. In 
fact, it was only upon adding adenosine to the organ bath prior to the hypoxic event that we were 
able to witness any sort of effect within the tissues. Upon adding large amounts of adenosine 
(millimolar range) which is not physiologically relevant (adenosine is usually found in the 
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nanomolar - micromolar range), we were able to witness what appears to be preconditioning 
resulting in a vascular protective effect in all but one concentration in the ENT1+/+ and at the two 
highest concentrations within the ENT1-/- mice.  
This high quantity of adenosine was able to elicit a protective effect within the vasculature, 
which could indicate some level of A1 and A3 receptor expression is also present in the 
vasculature although perhaps not at a high enough quantity to elicit this type of response at a 
naturally occurring concentration of adenosine. This effect is not conclusive and may also be an 
unrealized consequence of A2 receptor activation. The activation of A1 and A3 receptors has been 
shown to be responsible for the cardioprotective effect, and although there is evidence of the A2A 
and A2B receptors being of importance in the ischemia reperfusion model, possessing all 
receptors is required to elicit a similar outcome as has been seen in the studies done by Rose et 
al. (2009) [33]. It is not surprising therefore that although the tissue is from the same mouse the 
vascular protective effect we had hoped to see did not occur. It is reasonable to speculate that the 
A1 receptor distribution was not abundant enough, if present at all, within the vascular tissue, to 
produce a similar response as what is witnessed in the heart.  It is important to note that due to 
tissue handling, the vascular rings may not have a fully functional endothelium. Methacholine 
was used to elicit a vasodilation response to ensure the integrity of endothelium and the tissue 
was used only upon the generation of a strong response however the process of excising the 
tissue and removing the fatty tissue still results in some mechanical damage and a partially 
denuded artery can result in varying results. 
In addition to the preconditioning effect of adenosine in both genotypes, hypoxia induced 
vasoreactivity was examined in the aorta. It is expected that adenosine release in ENT1+/+ aortic 
segments should be higher than that in ENT1-/- aorta,  ideally indicated by a higher degree of 
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relaxation, however, in both the carotid arteries and the aortas, neither result was significant nor 
did it appear as if much vasodilation occurred (Figure 3.13).  Even if vasodilation had been 
observed, the possibility exists that another agent involved in vasodilation was at work, such a 
prostacyclin, bradykinin or NO, which would have been indicated by hypoxia vasoreactivity. It is 
also possible that the role of extracellular ATP breakdown as a source of adenosine is being 
underestimated which is resulting in the inability to distinguish between the two genotypes in 
terms of potential adenosine release.  
In a tissue experiment it is expected that some fluctuations in contraction will occur past the 
point of what appears to be plateau thus the measurements over the course of an hour will vary. 
The possibility exists that the lack of significant difference between genotypes could be 
indicative of a down-regulation of CD73 or CD39 within the ENT1-/- which could have further 
effects within the cell. Reasons for a negative response could be potential release of other 
receptor agonist counteracting the suggested adenosine vasodilation. Marshall (2000) 
hypothesized that circulating constrictors such as catecholamines and vasopressin need to be 
overcome by the vasodilator, and the degree vasodilation varies depending on the level of 
hypoxia in that area [82]. 
4.5 Expression of target genes Ada, Ak and Catalase, in the descending thoracic aorta were 
not significantly different between genotypes 
Adenosine formation can be carried out by dephosphorylation of AMP and can be removed 
via deamination in which the adenosine metabolite inosine is formed, or phosphorylation in 
which AMP is formed. Adenosine deaminase to form inosine is carried out by the enzyme 
adenosine deaminase (ADA).  Similarly, adenosine kinase (AK) is responsible for 
phosphorylation to AMP. Due to relatively high levels of AMP, ADP and ATP compared to the 
97 
 
levels of adenosine within the tissue, AMP/adenosine substrate cycle changes have relatively 
little effect on the concentrations of AMP, ADP or ATP, however changes in the AMP/adenosine 
substrate cycle will have a large impact on the adenosine concentrations within the cell.  
Previous work done by Rose et al. 2011 showed that blood serum concentrations of 
adenosine within the ENT1-/-
 
mouse were significantly higher with almost double the 
concentration [52]. This change may suggest a decrease Ak expression and/or perhaps a decrease 
in Ada expression. ENT1-/- mice were observed to have increased extracellular adenosine 
compared to ENT1+/+ mice indicating that some extracellular adenosine is being transported 
across the membrane in the ENT1+/+ [52]. It therefore also follows that intracellular levels of 
adenosine in the ENT1-/- may be decreased as well. As such, a decrease in intracellular adenosine 
could result in a decrease in Ak or Ada expression. If intracellular adenosine concentrations are 
low, ADA may be down-regulated to conserve the adenosine stores and reduce activity of the 
xanthine oxidase pathway. As previously described, the xanthine oxidase pathway results in the 
generation of ROS, which can be detrimental to the cells. However, recent studies have also 
shown the benefits of xanthine oxidase in relation to disease states in which the ROS it generates 
are involved in an antimicrobial response, and currently not much is known about all the effects 
of xanthine oxidase [83]. It therefore would be plausible that Ada expression could be increased 
or decreased, although as the mice in the current study were not chronically ill with a microbial 
infection, it is more likely that Ada expression would have been down-regulated. AK on the 
other hand would more likely have been down-regulated in response to the decreased adenosine 
with less adenosine to convert to AMP. As previously described, AK is at maximum saturation 
during resting periods therefore, without a decrease in Ak expression, AK would be in excess. 
Neither of the proposed theories were corroborated as expression levels of Ada and Ak were 
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found to be unchanged in the aorta of ENT1-/- mice, and if there had been a down-regulation of 
Ada expression, the expected result would be a decrease in inosine concentration. Previous work 
carried out in cardiomyocytes of the ENT1-/- and ENT1+/+ found inosine levels following a 
hypoxic challenge to be not significantly different, however this work has not been replicated in 
tissue [52].  
Expression of catalase was also found to be unchanged in the aortas ENT1-/- mice. Catalase 
is an enzyme which is responsible for the protection of cells from oxidative damage via the 
conversion of hydrogen peroxide to water and oxygen. The formation of xanthine and 
hypoxanthine resulst in the production of ROS and it had been hypothesized that catalase would 
be up-regulated due to the increased production of ROS via the subsequent metabolite formation 
of inosine, xanthine and hypoxanthine from adenosine. The inability of adenosine to transport 
out of the cell would hypothetically result in the increased production of ROS and therefore a 
need for an increase in antioxidant activity.  
Expression of ENT1 was found to be non-existent in the aortas of ENT1-/- mice. The 
transporter is necessary for adenosine transport into and out of the cell and its loss, which is the 
focus of this study, would hypothetically result in increased activation of adenosine receptors on 
the outside of the cell, a mechanism which has been indicated in the cardioprotective effect seen 
in ischemic reperfusion therapy. However low extracellular adenosine production could result in 
the lack of positive correlation we are seeing between loss of the transporter and vascular 
protection. It is estimated that 30% of adenosine production in the endothelial cells is a result of 
ecto-5ʹ-nucleotidase, and only 24% in smooth muscle cells [84]. Low levels of adenosine 
production in extracellular, relative to intracellular adenosine production; suggest that adenosine 
receptor stimulation may be attenuated by the efflux of adenosine. If these estimations are 
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correct, the ENT1-/- inability to transport adenosine outside of the cell may result in decreased 
adenosine receptor activation. 
4.6 Summary and Conclusions 
The studies carried out in this thesis were based on the pre-existing knowledge that 
connects adenosine and cardioprotection as well as the extensive research done within this 
mouse model in which an ischemic event within the heart has shown to exhibit a cardioprotective 
effect through alteration of purinergic signaling after exposure to a hypoxic challenge. 
 
We hypothesized that: Loss of ENT1 will lead to a vascular phenotype due to disruption of 
the normal purinergic homeostatic mechanism which is critical to vascular regulation. 
Working Hypothesis: Loss of ENT1 will result in an increase in interstitial adenosine levels 
leading to compensatory changes in the vasculature that would mimic preconditioning. 
We explored this hypothesis with the following objectives: 
1) To determine the baseline vascular characteristics of the ENT1-/- mouse versus the 
ENT1+/+ mouse. 
2) Examine the aorta looking for structural differences between the ENT1 -/- and 
ENT1+/+ mouse. 
3) Examine the vascular tissue in response to hypoxic conditions. 
We then characterized the ENT1-/- mouse vasculature looking specifically at morphological and 
functional differences. 
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Conclusion 4.1: Mice lacking ENT1 demonstrate no morphological differences or calcium 
deposits in the vascular tissues of the aorta or carotid arteries. Although there is evidence that 
ENT1 has a role in the regulation of soft tissue calcification, no mineralization is present within 
the first four months [32].  
Conclusion 4.2: Mice lacking ENT1 possess an elevated blood pressure while conscious 
however no differences were seen while anaesthetized, nor were any differences seen in their 
heart rates.   Mice lacking ENT1 had smaller lumens and increased aortic stiffness which was in 
line with the findings. The increased blood pressure could be the result of the narrowing of the 
lumen, resulting in increased vascular resistance. 
Conclusion 4.3: Mice lacking ENT1 were smaller in body weight and possessed a lower RER 
and EE while maintaining a higher level of activity during the dark cycle, all of which support 
prior evidence of leaner mice [29]. This indicates that adenosine signaling and transport plays a 
role in fat metabolism, accounting for the leaner appearances and lower body weight.   
Within chapter four, we also sought to assess potassium mediated depolarization as well 
as receptor mediated constriction in both normoxic and hypoxic conditions.  
Conclusion 4.4: ENT1-/- had increased response to potassium chloride which indicates that there 
is either an increased responsiveness to depolarizing agent or a feedback response of adenosine 
on ENT1+/+ tissue. The study indicated that the increased response is a result of increased 
responsiveness to depolarizing agents rather than a feedback response.  The reason for this 
conclusion was based on the results of the study which clearly demonstrated that inhibition of the 
transporter did not result in increased depolarization. A more reasonable conclusion is that the 
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increased reactivity to KCl is a result of the increased arterial stiffness observed in the length-
tension curves. 
Conclusion 4.5: Loss of ENT1 does not lead to any increased or decreased response in receptor 
mediated contraction, within the tested receptors, during normoxic conditions. It is reasonable to 
conclude that ENT1-/- mice do not possess differences in FP, 5-HT2
 
or α1-adrenergic receptor 
within the descending thoracic aorta, with respect to distribution or relative abundance in the 
tissue as compared to controls.  
Conclusion 4.6: Loss of ENT1-/- allowed for a greater vasodilation compared to control in aorta.  
This supports the theory that adenosine levels remain higher for a longer period of time at the 
receptors, due to the inability to transport across cell membranes. 
Conclusion 4.7: Blocking A2A receptor resulted in less vasodilation in the control and ENT1-/- of 
both the aorta and carotid arteries when compared to adenosine vasodilation in the absence of 
A2A blocker. This indicates that the main mechanism of vasodilation is via A2A receptors within 
the vasculature. 
Conclusion 4.8: Loss of ENT1 resulted in no contractile response changes in response to hypoxic 
conditions, nor did blocking the transporter result in any increased response to phenylephrine in 
the control mice. This indicates that the ENT1-/- mice are not vascular protected, and leads us to 
the hypothesis that perhaps intracellular adenosine generation and efflux plays a larger role in the 
preconditioning effect than previously speculated, hence the decreased reactivity following 
hypoxia in the ENT1-/- mice. 
Conclusion 4.9: Pre-treatment with adenosine in the control groups as well as the ENT1-/- mice 
results in increased reactivity post hypoxia, however the dose required to elicit this result in 
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ENT1-/- is higher than in mice possessing ENT1, again indicating that extracellular adenosine 
could play a more integral role in vascular protection than originally thought. 
Conclusion 4.10: Ada, Ak and catalase gene expression was not changed between genotypes 
indicating that the differences observed between the genotypes are not a result of decreased 
adenosine metabolites within the cell although the possibility exists that activity differences in 
enzymes are affecting metabolite production.  
4.7 Significance of Research 
Adenosine is an important signaling molecule in cardiovascular physiology, which has 
been the focus of many studies, and its effect in the protection against ischemia reperfusion 
injury is well documented.  It is required for ATP and nucleic acid synthesis within the body 
which is important in cellular physiology however its effects in the mediation of ischemia 
reperfusion injury make it a significant factor in the mediation of cardiovascular health, and 
particularly significant in this research.  
Numerous studies have been carried out in which manipulation of the upstream and 
downstream regulators of adenosine, such as CD39 and CD73, have resulted in a decreased 
cardioprotective effect due to the inability to synthesis adenosine. Studies in which adenosine 
transport into and out of the cell have been blocked using ENT inhibitors, such as NBMPR, have 
demonstrated an increased cardioprotective effect in the cells after a subsequent ischemic event.  
Work completed with this particular ENT1-null mouse model has yielded similar findings in the 
cardiac tissues.  
Studies carried out by Rose et al. (2009) showed a decrease in infarct size in the ENT1-/- 
versus the mouse possessing the transporter [33]. The purpose of the study was to investigate the 
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mechanism underlying the protective effect of the loss of ENT1 within the vascular tissues of 
this mouse model.  This study was unable to mimic the results seen in the cardiac tissue within 
the vasculature however, and in fact saw the opposite effects as would be expected. This result 
could be due to increased importance of extracellular adenosine levels rather than the release 
from the tissues themselves to initiate a vascular protection effect. In addition, hypoxia within 
the vasculature is not uniform and therefore responses to hypoxia are not entirely mediated in the 
same manner. Hypoxia-induced dilation factors are close to or produced near individual vessels 
based on oxygen depletion (Marshall, 2000) [82]. Our results varied greatly from the results we 
expected. Our expectations were based largely on the literature and the observations by Rose et 
al. which showed positive correlation between loss of ENT1 and cardioprotection [33,52]. The 
assumptions were also predicated on the vasculature possessing A2A and A2B receptors for which 
the extracellular adenosine could act on. However a relatively recent study (Zhan et al. 2011) 
that claimed the need for more than one receptor subtype, i.e. the need for all subtypes, A1, A2A , 
A2B and A3, to mediate a protective effect was not taken into account, but as mentioned in 
chapter 1, A1 stimulation resulted in decreased infarct size and positive postischemic function 
[16]. The literature is not all encompassing and the vasculature is largely excluded from the 
discussion on hypoxia and protection. A recent study (Rath et al. 2012) found that ischemia 
reperfusion resulted in the reduction of NO-mediated relaxation but increased endothelium-
derived hyperpolarizing factor (EDHF) mediated relaxation, however vascular hypoxic 
preconditioning  was able to attenuate the reduction in NO-mediated relaxation as well as 
increase EDHF mediated relaxation. Further analysis of this study also found that transient 
receptor potential cation channels V4 (TRPV4) also directly affects the NO-dependent pathway 
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therefore participating in vascular protection [85]. This study is mentioned to illustrate the depth 
to which vascular protection is relatively unknown. 
Studies of gene up-regulation and down-regulation could explain the effects of long term 
exposure to an ENT1 inhibitor such as NBMPR. The potential uses of ENT1 inhibitors in 
cardioprotection therapies require long term studies of the effects on the whole organism and this 
mouse model provides an avenue for the investigation of any “off-target” effects. Clinically, 
ENT1 inhibition has been considered as a potential treatment prior to ischemic reperfusion and 
these studies will help elucidate the effects of long term exposure within a mouse model. 
The ENT1-null mouse model is a potentially useful model for understanding the long 
term consequences of chronic inhibition of adenosine transport. This model may also be useful 
for investigating the importance of intracellular versus extracellular adenosine during the process 
of ischemia-reperfusion. This study could lead to further discoveries of risk factors and assist in 
identifying limitations of use in other vascular tissues. 
4.8 Limitations of Research and Suggestions for Future Studies 
This study is the first analysis of the vascular system in these ENT1-/- mice and therefore 
there is still much to be done. Gene expression studies were undertaken to elucidate the 
regulation of adenosine within the vascular tissues (Ada, Ak, ENT1, Catalase) within the ENT1 
mouse model however there are further genes of interest which could be further characterized 
such as xanthine oxidase, ecto-5ʹ-nucleotidase and other ENT/CNTs and adenosine receptors.  
 Following gene analysis, protein detection of these gene products is important in 
developing the repertoire of information in studying and reaching conclusions in this type of 
research. We cannot make any conclusive statements about the mechanism of vasoreactivity 
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within these mice without conclusive data and therefore further observation is required. 
Additional studies of these mice at different ages is also necessary as there may be further up- or 
down-regulation of gene products over time which could lead to morphological changes within 
the tissues of these animals. From previous work done within the lab, it has been concluded that 
mineralization of the vertebral column resulting in lesions becomes apparent at the age of six 
months. This suggests the possibility that further along in development, that phenotype may lead 
to complications within the vasculature of the mice. 
In addition to these approaches, tests can be done in which the hypoxic period is 
expanded. Hypothetically, an increased hypoxic period will result in increased damage to the 
vascular tissue. If we increase the period of hypoxia a more pronounced difference between the 
ENT1+/+ and ENT1-/- may become apparent. Further experiments could also examine the use of 
inhibitors of adenosine formation or breakdown, such as the 5ʹ-nucleotidase, adenosine 
deaminase or adenosine kinase. The scale of the experiments may also be increased in which 
whole organisms are subjected to hypoxic conditions and vascular tissues are tested. This could 
prove useful in the characterization of the differences of the effects seen in this study, which are 
clearly evident in the vasculature; thus providing the opportunity for comparative data on the 
protective effects on a larger scale. All testing was done on the aorta and in some cases the 
carotid arteries however, even slight changes to vessels such as the mesenteric arteries which 
supply the gut, can have a large impact on the functioning of the body. 
In conclusion, all previous studies should be carried out in the peripheral vessels as well 
to access whether similar findings are present, and proposed future studies should elaborate on 
what this study has established. The proposed experiments will further clarify the mechanisms 
involved in the potassium mediated response and the apparent changes in vasoreactivity in the 
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mice lacking ENT1, and will ideally provide a model for examining vascular effects of 
adenosine as well as downstream metabolites. 
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